Platform data discovery. EMIF Data Catalogue text-book example EMIFs mission improve identification, access assessment, (re)use health data within European Union. Toggle navigation EMIF CATALOGUE Access EMIF Catalogue via information project lifetime, European Medical Information Framework (EMIF) ha developed made EMIF Data Catalogue publicly available research community. EMIF Data Catalogue text-book example EMIFs mission improve identification, access assessment, (re)use health data within European Union. EMIF Catalogue allows user explore population-based (e.g. Electronic Health Record (EHR)-derived, Regional databases, etc.) cohort-derived (predominately within Alzheimers Disease) data source consented provide information purpose bona fide researcher wanting explore potential data partner studies. June 2018, 18 population-based 55 cohort-based data partner contained within Catalogue, across 14 country collaborating within EMIF. currently 800 unique user Catalogue home 8 different community far (eg. EPAD, MOCHA, ADVANCE, ). latter clearly indicates tremendous need EMIF Catalogue. Catalogue initially offered high-level meta data information data source, additional tool developed installed allow data source suitability evaluation initiate new research study data source secure environment. would welcome enquiry related Catalogue, indeed feedback user following access approval (questions feedback via, within Catalogue). Access Catalogue via following steps: Please access Catalogue . accessing Catalogue log-in front-end page, please click Create Account follow instruction provided, Sign In. Following Sign In, user able access EHR-derived and/or cohort-derived community pending approval Community Manager. User support via left-hand navigation panel, inclusive help function. behalf EMIF hope EMIF Catalogue significant asset EU research community, look forward continued development use, eventually within broader research platform communities. content Copyright EMIF, right Reserved. Last update 30-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation HOME Welcome website European Medical Information Framework (EMIF) project. EMIF wa public-private consortium 57 partner ran 5,5 years, ending June 2018. time span, EMIF ha successfully improved access human health data via providing tool workflow discover, assess, access (re)use human health data. Access EMIF Data Catalogue EMIF Platform EHR Video animation provides overview service approach IMI project EHR-derived, population data Published 02/05/2015 09:18 EMIF Platform Cohort Data Video video provides overview service approach IMI project cohort-derived data Published 02/05/2015 09:18 content Copyright EMIF, right Reserved. Last update 27-07-2021. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation combination rapidly increasing medical knowledge advance information technology allowing researcher use human health data way previously unimaginable. Increasingly, challenge find sufficient data fuel research. time, huge volume suitable data already collected stored electronically, routine Electronic Healthcare Record (EHR) databases, research-driven cohort study associated biobanks sources. However, data exists disparate location systems, generally used isolation. rarely aggregated larger datasets, meaning full potential realised. Additionally, privacy, legal ethical issue related data use also need properly addressed. EMIF Introductory Video animation provides brief introduction EMIF project key goal help improve access patient-level data, European Medical Information Framework (EMIF) wa launched January 2013. EMIF project five-year project time itwill develop common technical governance solution improve access use health data. aim, common Information Framework () link facilitate access diverse medical research data sources. ensure immediate applicability, EMIF project includes two specific therapeutic research topic help guide development Information Framework: onset Alzheimers disease () metabolic complication obesity (). EMIF receives support Innovative Medicines Initiative Joint Undertaking (IMI-JU) grant agreement n 115372, resource composed financial contribution European Unions Seventh Framework Programme (FP7/2007-2013) European Federation Pharmaceutical Industries Associations (EFPIA) kind contribution. Links relevant project :The EHR4CR project one largest public-private partnership aiming providing adaptable, reusable scalable solution (tools services) reusing data Electronic Health Record system Clinical Research. Electronic Health Record (EHR) data offer large opportunity advancement medical research, improvement healthcare, enhancement patient safety :aims show robust new method RWE collection synthesis could adopted earlier pharmaceutical R&D healthcare decision making process (I~HD):The vision ofi~HD become European organization reference guiding catalyzing best, efficient trustworthy us health data interoperability, optimizing health knowledge discovery :The EPAD project part global effort fight Alzheimers disease major European initiative create novel environment testing numerous intervention targeted prevention Alzheimers dementia :Dementias PlatformUK aUK powerhouse dementia research designed tofast-track scientific understanding, treatment prevention disease EMIF Brochure available downloading PDF version EMIF Brochure providing overview main achievement date. content Copyright EMIF, right Reserved. Last update 08-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation EMIF-PLATFORM EMIF Platform EMIF-Platform Project Overview EMIF ha ultimately build integrated, efficient Information Framework consistent re-use exploitation available patient-level data support novel research. supportdata discovery,data evaluationand then(re)use. EMIF-Platform System Overview EMIF-Platform ha developed platform allowing access multiple, diverse data sources. EMIF-Platform made data available browsing allows exploitation multiple way end user. EMIF-Platform ha leveraged data 62 Million European adult child mean federation healthcare database cohort 7 different country (DK,IT, NL, UK, ES, EE), designed representative different type existing data source (population-based registries, hospital-based databases, cohorts, national registries, biobanks, etc.). EMIF Data Catalogue available outside EMIF bona fide researcher information via . EMIF Platform EHR Video video provides overview service approach via EHR data post-IMI EMIF Platform Cohort Video video provides overview service approach via Cohort data post-IMI EMIF-Platform Objectives achieve EMIF-Platform objectives, project wa divided eight work package (WP9-WP16 below). addition, explore. EMIF-Platform Work Packages WP16 Use sustainability models, community building & outreach WP15 Use sustainability models, community building & outreach WP14 Architecture, solution development, security & privacy technology WP13 Analysis, processing & visualization method tool WP12 Data extraction, benchmarking, aggregation & linkage WP11 Harmonization & Semantics WP10 Governance WP9 Framework Requirements& Evaluation EMIF-Platform Achievements Tool Development Key tool developed data shop window support platform architecture, also utilised initiative (ADVACE, MOCHA, IMI-EPAD, DP-UK) Development & integration TASKA EMIF catalogue manage workflow. Common Data Model EMIF: OMOP-CDM, OHDSI Mapped 10 European Databases OMOP-CDM Contributes extension CDM Standardized Vocabularies accommodate European data Supports European OHDSI initiative stimulate adoption CDM collaboration across Europe Atlas ATLAS tool developed OHDSI used conduct scientific analysis standardized health data EMIF evaluating OHDSI tool EMIF community actively contributing development Biomarker Discovery Raw cohort data integration analysis via tranSMART allied bioinformatics tooling development support biomarker discovery AD metabolic disorder 3423 subject 14 AD cohort harmonized Support multi-omics data analysis. EMIF-Platform Tools Workflow Management Workflow Management Private Remote Research Environment (PRRE) Private Remote Research Environment (PRRE) Variable Selection Tool (VST) Variable Selection Tool (VST) ParticipantSelection Tool (PST) ParticipantSelection Tool (PST) CohortSelection Tool (CST; Catalogue) CohortSelection Tool (CST; Catalogue) Switchbox Switchbox Private Remote Research Environment (PRRE) Private Remote Research Environment (PRRE) Workflow Management Workflow Management OMOP CDM/OHDSI Tools OMOP CDM/OHDSI Tools EMIFCatalogue EMIFCatalogue Data extractiontooling Data extractiontooling Ethical Code Practice (ECoP) Ethical Code Practice (ECoP) EMIF-Platform Tools Governance & Security/Integration Layer Cohort architecture support EMIF-AD data discovery & (re)use workflow EHR architecture support generic data discovery & (re)use workflow Datare-use Dataaccess Dataassessment Datadiscovery Datare-use Dataaccess Dataassessment Datadiscovery EMIF-Platform Tools Governance & Security/Integration Layer Cohort architecture support EMIF-AD data discovery & (re)use workflow EHR architecture support generic data discovery & (re)use workflow Datare-use Dataaccess Dataassessment Datadiscovery Datare-use Dataaccess Dataassessment Datadiscovery WP 9 Framework requirement & evaluation Carlos Daz (Synapse) Peter Egger (GSK) Synapse (CO-LEAD), GSK (CO-LEAD), EMC, Janssen, UCL, PENTA, EMBL, EUROREC, UAVR, ULEIC, UPF, AP-HP, ARS, STIZON, AUH, GENOMEDICS, BIPS, PEDIANET, UTARTU, UNIMAN, BF, CUSTODIX, Pfizer, SERVIER, Amgen, UCB, MERCK, IDIAP JORDI GOL GOALS & OBJECTIVES objective are: continuously elucidate user requirement evaluate EMIF-Platform progressively developed deployed. cycle work plan, ensure adequate input prospective users, especially present future research projects, input EFPIA participants, important future user platform. cycle work plan, evaluate user perspective result cycle, feeding back development work packages. WP 10 Governance, federation, DB fingerprinting, legal context & ethic Nigel Hughes (Janssen) - TBD (EMC) EMC (CO-LEAD), JANSSEN (CO-LEAD), SYNAPSE, UCL, PENTA, EMBL, EUROREC, UPF, ARS, STIZON, AUH, GENOMEDICS, BIPS, PEDIANET, UTARTU, UNIMAN, BF, GSK, SERVIER, BI, Amgen, AE. IDIAP Jordi Gol GOALS & OBJECTIVES objective to: Provide detailed information (the fingerprint) participating database respect population included database, data available database, local data model, mechanism generating data, ability address specific re-use issue (such ability contact GP patients, inclusion patient clinical trials). Specify procedure followed governance federation, including required safeguard criterion admission. Define different type user EMIF-Platform, level access type user, procedure safeguard handle permissions. Ensure project followsethicalprinciples conforms relevant international national regulation regard. WP 11 Harmonization & semantics Dipak Kalra (UCL) Michel Van Speybroeck (Janssen) UCL (CO-LEAD), JANSSEN (CO-LEAD), EMC, UPF, AP-HP, ARS, STIZON, AUH, GENOMEDICS, BIPS, PEDIANET, UTARTU, UNIMAN, BF, GSK, SERVIER, ROCHE, IDIAP Jordi Gol GOALS & OBJECTIVES objective are: analyse harmonisation semantic needs, devise common framework reference guide interoperability work project, including metadata. develop common data model used throughout EMIF-Platform architecture represent query result set aggregate patient-level data. design implement service support specific cross-mappings terminology used clinical/medical terms, medicinal product unit measurement. WP 12 Data extraction, benchmarking, aggregation & linkage Peter Rijnbeek (EMC) Martijn Schuemie (Janssen) EMC (CO-LEAD), JANSSEN (CO-LEAD), UCL, UPF, ARS, STIZON, AUH, GENOMEDICS, PEDIANET, UTARTU, UNIMAN, BF, CUSTODIX, GSK, SERVIER, BI, Amgen, ROCHE, IDIAP Jordi Gol GOALS & OBJECTIVES objective are: develop common framework extracting data across different data sources. benchmark result extraction across different data source explicit objective account difference observed. provide tool linking data different source allow individual tracked data sources, taking account transition childhood adulthood. aggregate data order comply privacy governance rule control re-use data. WP 13 Analysis, processing & visualization method tool Alvis Brazma (EMBL) Rudi Verbeeck (Janssen) EMBL (CO-LEAD), Janssen (CO-LEAD), EMC, UCL, UAVR, ULEIC, UPF, UTARTU, UNIMAN, GSK, SERVIER, PFIZER GOALS & OBJECTIVES objective are: develop dedicated data analysis algorithm tool help exploitation data made available platfom, leveraging re-using possible already existing tools; develop visualisation tool EHR based generalisation concept genome browser distributed annotation systems; develop specific analysis tool broad translational research datasets used vertical project apply data analysis problem arising context projects. WP 14 Architecture, solution development, security & privacy technology Jos Luis Oliveira (UAVR) Philippe Baudoux (UCB) UAVR (CO-LEAD), UCB (CO-LEAD), EMC, Synapse, UCL, EMBL, EUROREC, ULEIC, UPF, PEDIANET, UNIMAN, CUSTODIX, Janssen, SERVIER, Amgen GOALS & OBJECTIVES objective are: engineer ICT infrastructure federation resources, including dynamic support common data model variable operation procedures. provide technical infrastructure secure, cross-project data exchange. create development environment EMIF-Platform ecosystem, enabling creation software clinical information browser, evolving biomedical knowledge base Private Remote Research Environments. WP 15 Use sustainability models, community building & outreach Eva Molero (Synapse) Bart Vannieuwenhuyse (Janssen) Synapse (CO-LEAD), Janssen (CO-LEAD), EMC, UCL, PENTA, EMBL, EUROREC, UAVR, ULEIC, UPF, AP-HP, ARS, STIZON, AUH, GENOMEDICS, BIPS, PEDIANET, UTARTU, UNIMAN, BF, CUSTODIX, GSK, SERVIER, Amgen, ROCHE, IDIAP Jordi Gol GOALS & OBJECTIVES objective are: analyze need different key stakeholder (potential user platform) aim develop sustainability model (business model) serf need acceptable data custodian develop test different sustainability model derived analysis above, ensure long-term maintenance operation information framework developed project. Outreach: WP15 also aim connecting EMIF relevant project (IMI other) ha ambition identify connect new data source network. WP 16 Use sustainability models, community building & outreach Carlos Daz (Synapse) Bart Vannieuwenhuyse (Janssen) EMIF partner GOALS & OBJECTIVES objective are: overall objective WP ensure successful implementation project scientific, financial management level. achieve focus 4 main area : Ensure efficient management scientific activity financial allocation/reporting, organisation project meeting Ensure effective communication partner support sharing best practice, maximise synergy prevent duplication Designing implementing dissemination plan communication strategy Managing Intellectual Property right deriving value foreground information generated Ensure appropriate risk management, particularly joint risk across whole programme interface three topic EMIF Code Practice (ECoP) EMIF platform used for: assessing feasibility study conducting research bona-fide research organisation objective discovering new knowledge intended public good made publicly accessible (i.e., published) ECoP wa developed order help ensure that: EMIF Platform Services used way comply legislation, 2018 European GDPR policy data protection EMIF upholds best practice protection personal privacy information governance EMIF promotes best practice conduct clinical research using health data, public good Data source Data user always autonomy data made accessible type research must adhere ethical rule privacy protection policy data source always determine ethical acceptability scientific validity may use data specific agreed research purpose must transparent data must acknowledge source data used, EMIF EMIF Catalogue key idea EMIF Catalogue allow researcher find specific database aligned research purposes, providing summarized overview number geographically scattered healthcare databases. accomplish this, EMIF Catalogue flexible web system supported Community concept, i.e., group joining database user clinical interests. Features: Community-based access management Database fingerprinting Free text advanced search Suitability assessment (through Jerboa Achilles) Distributed management group data Role-Based access control (RBAC) Open architecture (plugin-based) TASKA TASKA innovative platform designed streamline creation modular easily extendable workflow manage data extraction handling general work processes. based Software-as-a-Service approach, making versatile easy integrate third party applications. platform allows several user collaborate interact creation execution distributed workflows, relying easy-to-use interface managing complex procedures. Features: Easy-to-use visual editor Task definition, inputs, outputs, dependency Questionnaire task Workflow scheme (templates) Running study (workflows) Task assignment notification Web service allow system operate without interface Jerboa Reloaded Work package 12 (Data extraction, benchmarking, aggregation & linkage) mainly involved important challenging task develop complex scenario informed consent cannot obtained. example, case electronic healthcare record (EHR) collected general practitioners, access patent data often restricted anonymized aggregated data. Jerboa Reloaded extraction tool developed EMIF project support data extraction processing EHR databases. used so-called distributed network design, i.e. run de-identification, linkage, analysis aggregation locally data source site. Jerboa run script contains parameter specific study design. ha advantage local analysis performed common, standard way subject small difference implementation local statisticians, study-only data necessary particular study shared analytical dataset. OCTOPUS Private Remote Research Environment OCTOPUS infrastructure used prototype private remote research environment (PRRE) WP12. allows secured file transfer data custodian used collaborate aggregated data generated Jerboa Reloaded. OCTOPUS remote research environment socio-technological framework ha developed Erasmus MC past, ha already proven value various projects. stimulates geographically dispersed research group collaborate ha resulted consortium engaged phase drug safety research. achieve successful sustainable collaboration, database custodian data suppliers. custodian reside research institutes, analytical task distributed well. main purpose OCTOPUS stimulate collaborative drug safety research secured environment. EMIF dedicated PRRE currently developed scalable optimized based experience OCTOPUS. Participant Selection Tool Participant Selection Tool allows researcher get overview patient profile given cohort, filtering set predefined key characteristics. tool ha currently built provide capability AD cohort data sets. user interface designed minimise learning curve. Federated data source represented single tabular graphical view. Filtering categorical, date continuous key variable possible result count number matching patient across different cohorts. basis tool Knowledge Object. knowledge object ontology different data source (in case cohort data) mapped. use semantic technology offer required flexibility ontology develops additional data source added. tool accommodate different project (e.g. single data source participating one projects) additional characteristic added given project. framework also used develop additional tools, ultimately enabling integrated data pipeline cohort data. Virtual Selection Tool (VST) VST provides researcher overview available variable (counts, values), followed data access request selected cohort owners. TranSMART TranSMART knowledge management application built open source component investigate correlation genetic phenotypic (clinical) data aid predictive biomarker discovery. consists web-based graphical data mining application connects server based data warehouse. TranSMART wa made open source 2012. tranSMART Foundation wa established 2013 provide governance coordination new developments. Important contribution come IMI eTRIKS, CTMM TraIT, Pfizer, Sanofi Janssen, amongst others. TranSMART combine clinical high dimensional data, gene expression, single nucleotide polymor-phisms (SNPs), Rules-based medicine (RBM), genome-wide association study (GWAS), copy number variation (CNV), etc. EMIF, main emphasis ha harmonized clinical data. High dimensional data expected e.g. EMIF-AD 1000 sample cohort. TranSMART allows easy generation query phenotypes, genotypes, combination. Study group formed ad hoc generate summary statistic hypothesis testing. Several advanced analysis pipeline built in, boxplots ANOVA, scatter-plots linear regression, Kaplan-Meier plot survival analysis, etc. GenePattern functionality available gene expression proteomic analysis. Subjects individual cohort pooled virtual cross trial cohort unified data analysis. Multi-omics Research Environment (MORE) Cloud computing provides user number benefits: reduction computational costs, universal access, date software, choice applications, flexibility. many cloud platform Research project choose from: Amazon Web Services, OpenStack, VMWare, Google Cloud, etc. transferrable solution different cloud platform ha specialised component clinical omics data analysis. addition, implies flexible architecture allows adding new tool pipeline upon request. following pipeline tool currently available (version 2): tranSMART clinical data analysis; R Cloud R parallel computing R specific analysis; iRAP pipeline adapted Docker cluster analyse transcriptomics sequencing data; NGSeasy pipeline adapted Docker cluster analyse genomics sequencing data; MZmine2 adapted Docker cluster analyse proteomics metabolomics LC-MS data; Sequence Imp pipeline adapted Docker cluster analyse microRNA sequencing data. tranSMART, Docker cluster R Cloud connected use shared file system. Docker cluster R Cloud benefit scalability cluster computing usage multiple VMs, job queue task scheduler. New resource added needed. open-source project code publicly available at: . EMIF instance available EMBL-EBI Embassy Cloud accessible upon request EMIF users. instance used EMIF-AD biomarker discovery. Knowledge Object Framework Michel van Speybroeck, James Cunningham, et al. Janssen & UNIMAN knowledge object framework consists number component support harmonization effort clinical data. knowledge object semantic representation clinical variable contains descriptive metadata, executable rule specify relation (mapping) knowledge objects, actual data. local knowledge object representation source variable contains raw data. global knowledge object defines harmonized, cross trial variable serf mapping target local knowledge objects. Several level derived knowledge object possible, thus creating dependency graph. main goal knowledge object make data harmonization process efficient specifying minimal information understand clinical measurement mapping harmonized variable. information owned maintained local data source research community. specifying metadata mapping rule using semantic web technology reasoner used perform actual data extraction harmonization. Security restriction also defined local variable automatically propagated global knowledge objects. knowledge object framework consists following technical components: central knowledge object library contains definition core classes, property global knowledge objects. local ontology data source, developed using tool Protg (for definition local concepts) Pentaho (for specifying mapping rule connection local data sources). Executing mapping rule result local dataset, harmonized global standard stored Stardog triple store. Stardog sparql API make data available federated query outflow tool Participant selection Tool Variable Selection Tool. OMOP CDM/OHDSI Tools OHDSI tool (e.g. ACHILLES) provides researcher overview patient profile given cohort, filtering limited set pre-agreed characteristics. Mapped 10 European Databases OMOP-CDM Contributes extension CDM Standardized Vocabularies accommodate European data Supports European OHDSI initiative stimulate adoption CDM collaboration across Europe Atlas ATLAS tool developed OHDSI used conduct scientific analysis standardized health data EMIF evaluating OHDSI tool EMIF community actively contributing development Workflow Management Workflow management ensures integrity process researcher data sources; management task process steps. Workflow Managment Workflow management ensures integrity process researcher data sources; management task process steps. Switchbox Switchbox provides single interface cohort owners, multiple harmonised output tools. Corhort Selection Tool (CST) CST provides researcher overview potential cohort data, availability, suitability. content Copyright EMIF, right Reserved. Last update 09-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation EMIF-AD EMIF-AD Project Background multiple clinical trial dementia failing past years, attention ha recently shifted subject Alzheimers disease (AD) reached stage dementia yet (i.e., pre-dementia). Since subject limited brain damage suggested likely responsive treatment subject full-blown dementia, important target group future treatment studies. EMIF-AD Project Objectives Trial design pre-dementia AD, however, challenging subject pre-dementia AD difficult identify limited information available outcome. lack reliable diagnostic prognostic marker pre-dementia AD explained availability small-scale ongoing biomarker study longitudinal cohort including subjects. EMIF ha linked information unlocked true potential studies. connecting relevant cohort study across Europe, EMIF-AD ha set pan-European platform large-scale research biomarkers risk factor neurodegenerative disorders. biomarker discovery activity EMIF-AD driven extreme phenotype approach, decline biomarker status wa used end point biomarker discovery, rather clinical diagnosis. so, EMIF-AD ha developed new treatment targets, multimodality/omics diagnostic tool qualification level biomarker datasets suitable presentation regulatory authority prior approval use clinical trial practice. Finally, prediction rule cognitive decline presymptomatic prodromal AD developed improve clinical diagnosis prognosis, equally support subject selection stratification future clinical trials. achievement possible EMIF-AD combined large-scale patient cohorts, linkage EHR data, cutting edge biomarker discovery expertise. Work Packages Overview Identify predictor Alzheimers Disease (AD) pre-clinical prodromal phase Work Packages (WP) EMIF-AD Validate new biomarkers andselect subject prevention trial WP4 Biomarker discovery withextreme phenotype endpoint WP3 Characterise study populationand define extreme phenotype WP2 Define study population data collection WP1 EMIF-AD Project Achievements EMIF AD Catalogue Tools developed support data suitability via cohort selection patient profile selection research query user-friendly EMIF Catalogue publicly available search AD cohort interest Availability European AD cohort information one place facilitate future research collaboration Several initiatives, IMI-EPAD, DPUK, IMI-PRISM, JPND-EADB INTERDEM already taken EMIF Catalogue EMIF-AD Multimodal Biomarker Discovery study Project lead: Pieter Jelle Visser, VUmc Amsterdam & Maastricht University Simon Lovestone, Oxford University & Janssen Pharmaceutica Johannes Streffer, UCB & University Antwerpen Coordinator data management: Isabelle Bos, VUmc Amsterdam & Maastricht University, isabelle.bos@maastrichtuniversity.nl Aim & design: main aim EMIF-AD Multimodal Biomarker Discovery (EMIF-AD MBD) study wa accelerate discovery novel diagnostic prognostic biomarker AD unravel underlying pathophysiological mechanism using existing data samples. harmonized pooled clinical data 11 cohort study across Europe sample (cerebrospinal fluid, plasma, DNA) MRI scan centrally analyzed using different omics technique (proteomics, metabolomics, genomics). total, material 1221 participant wa included (n=492 control, n=527 MCI, n=202 AD dementia). Figure 1 provides schematic overview EMIF-AD MBD study. data generated context EMIF-AD MBD study available upon request approval research question parent cohort EMIF-AD team. Data request submitted via EMIF-AD Catalogue (). Scientific output Bos, I., Vos, S.J., Vandenberghe, R., Scheltens, P, Engelborghs, S., Frisoni, G., Visser, PJ (2018). EMIF-AD Multimodal Biomarker Discovery Study: Design, method cohort characteristics. Alzheimer Research & Therapy. Kate ten, M., Redolfi, A., Bos, I., Vos, S.J.B., Vandenberghe, R., Gabel, S., Barkhof, F. (2018) MRI predictor amyloid pathology: result EMIF-AD Multimodal Biomarker Discovery study. Alzheimer Research & Therapy. Morgan, A. R., Touchard, S., Leckey, C., OHagan, C., Nevado-Holgado, A. J., Barkhof, F., & Engelborghs, S. (2019). Inflammatory biomarkers Alzheimers disease plasma. Alzheimers & dementia. Kim, M., Snowden, S., Suvitaival, T., Ali, A., Merkler, D. J., Ahmad, T., & Hye, A. (2019). Primary fatty amide plasma associated brain amyloid burden, hippocampal volume, memory European Medical Information Framework Alzheimers Disease biomarker discovery cohort. Alzheimers & dementia, 15(6), 817-827. Bos, I., Vos, S., Verhey, F., Scheltens, P., Teunissen, C., Engelborghs, S., & Bordet, R. (2019). Cerebrospinal fluid biomarkers neurodegeneration, synaptic integrity, astroglial activation across clinical Alzheimers disease spectrum. Alzheimers & dementia, 15(5), 644-654. EMIF-AD 90+ study Project lead: Pieter Jelle Visser, VUmc Amsterdam & Maastricht University Stephan Carter, University Manchester Coordinator data management: Nienke Legdeur & Rene Haan, VUmc Amsterdam, r.haan2@amsterdamumc.nl Aim & design: EMIF-AD 90+ study aimed identify factor associated resilience cognitive impairment oldest-old. study wa conducted Amsterdam University Medical Center University Manchester. baseline, neuropsychological clinical data (vascular comorbidities, mood, sleep, physical performance, genetic factors) collected 129 participant (n=84 normal cognition n=38 cognitive deficits). Regarding imaging measures: baseline MRI (n=92), Amyloid-PET (n=103) MEG (n=92) collected. addition skin biopsy (n=99) ultrasound carotid artery (n=102) Currently (Oct 2019), first annual follow-up measurement completed n=129 November 2019, plan second annual follow-up 2020. Data request submitted via EMIF-AD Catalogue (). Scientific output Legdeur N., Tijms B.M., Konijnenberg E., den Braber A., ten Kate M., Sudre C.H.,& Visser P.J., Associations Brain Pathology Cognitive Physical Markers Age Cognitively Normal Individuals Aged 60102 Years, Journals Gerontology: Series A. Legdeur N., Badissi M., Carter S.F., de Crom S., van de Kreeke A., Vreeswijk R., & Visser P.J. Resilience cognitive impairment oldest-old: design EMIF-AD 90+ study. BMC Geriatr. EMIF PreclinAD study Project lead: Pieter Jelle Visser, VUmc Amsterdam & Maastricht University Stephan Carter, University Manchester Coordinator data management: Jori Tomassen, VUmc Amsterdam, j.tomassen@amsterdamumc.nl Aim & design: main aim EMIF-AD PreclinAD study wa indentify new risk factor diagnostic marker amyloid pathology cognitive decline cognitively normal subject without amyloid pathology. investigate monozygotic twin pair included genetic environmental pathway identified. baseline measurement n=204 cognitively healthy elderly monozygotic twin aged 60 year older included Manchester Newcastle Age Cognitive Performance Research Cohort Netherlands Twin Register. baseline following measurement done: neuropsychological examination (n=204), blood sampling (n=204), CSF collection (n=127), ultrasound carotid artery (n=102), magnetoencephalography (n=190) collection ophthalmological marker (n=198). n=192 (94%) following follow-up measure done two years: containing neuropsychological examination (n=191), blood collection (n=192) CSF sampling (n=103). second follow-up conducted 2020. Data request submitted via EMIF-AD Catalogue (). Scientific output Konijnenberg E., Carter S.F., Ten Kate M., den Braber A., Tomassen J., Amadi C., & Visser P.J. EMIF-AD PreclinAD study: study design baseline cohort overview. Alzheimers Res Ther. 2018 Aug 4;10(1):75. doi: 10.1186/s13195-018-0406-7. Konijnenberg E., den Braber A., ten Kate M., Tomassen J., Mulder S.D., Yaqub M., , & Visser P.J. Association amyloid pathology memory performance cognitive complaint cognitively normal older adults: monozygotic twin study. Neurobiology Aging. 2019 May; 77: 58-65. WP 1 Definition study population data requirement data collection Pieter Jelle Visser (UM) Michael Arrighi (Janssen) UM (CO-LEAD), JANSSEN (CO-LEAD), UNIMAN, VUMC, IRCCFS-FBF, MAAT, CAMCOG, BI, PFIZER, ROCHE GOALS & OBJECTIVES main objective is: overall aim WP collect data required development validation new biomarkers predementia AD overarching EMIF. data collected used analysis WP 2 WP 4. sub-objectives are: select cohort used biomarker discovery validation pool data cohort study Private Remote Research Environment link data research cohort EHR collect additional data key AD biomarkers cognitive marker subject ongoing longitudinal cohort study WP 1 Definition study population data requirement data collection Pieter Jelle Visser (UM) Michael Arrighi (Janssen) UM (CO-LEAD), JANSSEN (CO-LEAD), UNIMAN, VUMC, IRCCFS-FBF, MAAT, CAMCOG, BI, PFIZER, ROCHE GOALS & OBJECTIVES main objective is: overall aim WP collect data required development validation new biomarkers predementia AD overarching EMIF. data collected used analysis WP 2 WP 4. sub-objectives are: select cohort used biomarker discovery validation pool data cohort study Private Remote Research Environment link data research cohort EHR collect additional data key AD biomarkers cognitive marker subject ongoing longitudinal cohort study WP 2 Characterisation study population definition extreme phenotype M. Gordon (BI), G. Novak (Janssen), Engelborghs (UA), B. Dubois (UPMC) BI, Janssen, UA, UPMC, VTT, VUmc, Maastricht, UM, GSK, Pfizer, Roche, CamCog, Newcastle, KCL, Oxford GOALS & OBJECTIVES main objective are: characterize study population define extreme phenotype based subject selected WP 1 sub-objectives are: provide summary statistic cohort selected WP 1 operationalize criterion pre-symptomatic AD prodromal AD define extreme phenotype based rate decline develop multivariate prediction model cognitive decline define extreme phenotype based AD biomarkers define extreme phenotype based resilience dementia old age WP 3 Biomarker Discovery Simon Lovestone (UOXF) Johannes Streffer (Janssen) UOXF (CO-LEAD), Janssen (CO-LEAD), KCL, VUmc, UGOT, KI, VTT, IRCCS-FBF, PSPLC, VIB, MAAT, UZL, GSK, PFIZER, BI, ROCHE GOALS & OBJECTIVES main objective is: objective WP discover new biomarkers genetic marker diagnosis prognosis predementia AD using extreme phenotype defined WP 2. sub-objectives are: perform proteomics CSF plasma perform GWAS analyses, exome sequencing, assessment epigenomic profiles, transcriptome profiling perform metabolomics CSF plasma perform voxel based MRI analysis develop multivariate class prediction algorithm generate assay new biomarkers WP 4 Validation new biomarkers identification selection individual pharmacological intervention Hilkka Soininen (UEF) Piotr Lewczuk (UKER) Henrik Zetterberg (UGOT) TBD (Janssen) UEF (CO-LEAD), Janssen (CO-LEAD), VUmc, UGOT, IRCCS-FBF, UKER, MAAT, UZL, GSK, BI GOALS & OBJECTIVES main objective is: main objective WP cross-validate biomarkers discovered WP 3 independent sample develop recruitment strategy AD prevention trials. sub-objectives are: cross-validate new plasma, CSF, genetic MRI marker WP 3 independent cohort investigate relation genetic risk factor amyloid pathology neuropathological examination investigate relation new AD plasma marker long-term cognitive decline general population develop stepwise screening algorithm recruitment subject presymptomatic AD prodromal AD analyse data ongoing prodromal AD trial select site selection inclusion subject predementia AD trial content Copyright EMIF, right Reserved. Last update 17-12-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation EMIF-METABOLIC EMIF-Metabolic Project background Accumulating evidence indicates obesity closely associated increased risk metabolic complication type 2 diabetes, coronary heart disease, non-alcoholic fatty liver disease cancers. However, association obesity complication complex, high inter-individual variability susceptibility specific metabolic complication obesity. association expected additionally influenced different constitutional, environmental obesity-specific factors, thus complicating development adequate treatments. EMIF-Metabolic Project Objectives EMIF-Metabolic focus two distinct pathway individual obese may vary risk complication obesity. One identify genetic cause obesity relation metabolic complication obesity. pathway characterize individual identify marker associated metabolic risk irrespective degree obesity based knowledge many obese individual become dysmetabolic insulin resistant. instance complementary approach studying extreme phenotype population-based cohort followed. discovery predictor metabolic complication adult paediatric obesity ha lead innovative diagnostic tests, paved way novel therapeutic targeted high-risk individuals, provided infrastructure select individual targeted pharmacological intervention (genetic, epigenetic omics platforms). Identified novel mechanism potential target therapy characterized appropriate cell- animal-based model facilitate transition human studies. end, EMIF-Metabolic ha brought together top European expert genetics, epidemiology, genomics omic technologies, human murine physiology system approach state-of-the-art technologies. Work Packages Overview EMIF-MET Identify predictor metabolic complication obesity EMIF-MET Work Packages (WP) Evaluate epidemiology obesity-related clinical condition large real-world database WP8 Validate sensitivity/specificity novel biomarkers vs. currently available biomarkers WP7 Characterise heterogeneity metabolic consequence obesity small, medium large clinical population outcome data WP6 Identify novel biomarkers mechanism obesity-associated complication using extreme phenotype unbiased omics technologies, well targeted approach WP5 EMIF-Metabolic Project Achievements Cohort Development Molecules related insulin secretion capacity, insulin resistance NAFLD identified -omics biomarker discovery programme, currently undergoing validation sample set 6000 individual Discovery Potential new therapeutic target NAFLD/NASH investigation Platform database largest BMI cohort identified primary care patient WP 5 Use carefully characterized extreme phenotype identify biomarkers metabolic risk Peter Arner (KI) Markku Laakso (UEF) Dawn Waterworth (GSK) KI (CO-LEAD), UEF (CO-LEAD), GSK (CO-LEAD), UGOT, UCAM, UH, INSERM, ULEI, UGLA, VKJK, Janssen, PFIZER, NOVO, Amgen, BI GOALS & OBJECTIVES main objective is: characterize detail using omics technology extreme phenotype related complication obesity (including insulin resistance liver fat first degree relative diabetics). Response weight loss also characterized. interesting biomarkers subsequently evaluated tissue culture animal model taken forward validation medium sized cohort WP6. interesting marker correlated endpoint interest property would lend clinically useful; robustness, variability, frequency, tissue specificity ease detection. sub-objectives are: Detailed omics analysis well characterized sample extreme phenotype dietary intervention Comprehensive integrated analysis detailed omics data using data reduction/mining/statistical technique inform marker selection. Experimental assessment selected biomarkers cell-based animal model ass validity drug target diagnostic tools. WP 6 investigation heterogeneity metabolic consequence obesity medium-sized well phenotyped cohort study Nick Wareham (UCAM) Dawn Waterworth (GSK) Julia Brosnan (PFIZER) UCAM (CO-LEAD), GSK (CO-LEAD), PFIZER (CO-LEAD), UGOT, UH, UEF, INIPI, VKJK, ULEI, Janssen, Amgen, BI GOALS & OBJECTIVES main objective is: use candidate discovery approach identify biomarkers associated metabolic consequence obesity investigate causal significance medium-sized well phenotyped cohort large-scale nested case-cohort studies. sub-objectives are: select quantitative metabolic cohort study test biomarkers prediction metabolic consequence obesity. use candidate discovery approach identify potential biomarkers. study association likelihood causality biomarkers prediction metabolic consequence obesity. WP 7 Validate novel risk factor general population adult child Naveed Sattar (UGLA) Katrina Loomis (PFIZER) UGLA (CO-LEAD),PFIZER (CO-LEAD), UGOT,UCPH, Janssen, GSK, ROCHE, Amgen, BI GOALS & OBJECTIVES main objective is: overall objective WP measure test ability new metabolic biomarkers predict obesity-related outcome using retrospective prospective studies. sub-objectives are: Identify cohort EHR available baseline serum / plasma samples, acceptable phenotyping (i.e. conventional vascular risk factors, family history data level BMI waist circumference) access outcome vascular disease (i.e. CHD events), incident diabetes, obesity-related comorbidities fatty liver disease sleep apnoea. measure new biomarkers established biobanks available serum plasma cohort least conventional vascular risk factor measured baseline (plus BMI) documented outcome covering least CHD event potentially also including incident cancers, diabetes fatty liver disease. Compare ability biomarkers predict obesity-related outcome comparison conventionally measured risk factor simple demographic information. Test predictive capacity promising biomarkers utilising sample taken trial held Industry participant EHR/biobank studies. limited access sample biomarker analysis Confirming new metabolic biomarkers identified WP5 WP6 require EMIF bring additional biobanks cohort resource available biospecimens. WP 8 Identify select individual pharmacological non-pharmacological intervention Ele Ferrannini (UNIPI) Stuart Kendrick (GSK) Janet Addison (Amgen) UNIPI (CO-LEAD), GSK (CO-LEAD), Amgen (CO-LEAD), UCPH, Janssen, PFIZER, BI GOALS & OBJECTIVES main objective is: pharmaceutical intervention work package designed deliver real world observational data data randomised controlled studies, validating extreme phenotype approach classification obesity, disease related obesity, biomarkers identified work packages. also designed test feasibility electronic healthcare record driven recruitment intervention trials. sub-objectives are: Establish whether EHRs used conduct feasibility clinical trials? Establish whether EHRs used contact patient recruitment clinical trial Better understanding relationship (adverse effect & therapeutic effect) extreme phenotype response prescribed drug Validate biomarkers predict therapeutic response interventional trial Utilize clinical trial data generated EFPIA partner investigate liver complication obesity. content Copyright EMIF, right Reserved. Last update 10-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation CONSORTIUM project consortium partnership 58teams academia, small medium sized company member European Federation Pharmaceutical Industries Associations (EFPIA). EMIF team gather large number world-renowned expert data access linkage Metabolic AD therapeutic area 14 country across Europe. OrganisationPartner TypeCountry AcademiaDenmark AcademiaItaly Patient OrganisationLuxembourg EFPIAUK EFPIAGermany SMEUK SMEGermany SMEBelgium SMEUK AcademiaThe Netherlands AcademiaBelgium AcademiaGermany EFPIASwitzerland AcademiaItaly AcademiaItaly EFPIAUK AcademiaSweden AcademiaFinland AcademiaSpain AcademiaFrance AcademiaFinland EFPIABelgium AcademiaSweden AcademiaUK AcademiaGermany AcademiaThe Netherlands SMEFrance EFPIAGermany EFPIADenmark SMEItaly EFPIAUK SMEThe Netherlands AcademiaItaly EFPIAFrance SMESpain AcademiaEstonia AcademiaFinland EFPIABelgium AcademiaPortugal AcademiaSpain AcademiaBelgium AcademiaUK AcademiaDenmark AcademiaUK AcademiaUK AcademiaUK AcademiaUK AcademiaUK AcademiaFrance AcademiaItaly AcademiaGermany AcademiaGermany AcademiaGermany AcademiaGermany AcademiaBelgium AcademiaThe Netherlands content Copyright EMIF, right Reserved. Last update 10-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation GOVERNANCE Project Management Boards day-to-day management EMIF project done via various management boards, specific responsibilities. Project & Topic Leaders overall project coordination ensured by: Bart Vannieuwenhuyse, Janssen Pharmaceutica overall Project Coordinator Sir Simon Lovestone, University Oxford overall Project Co-Coordinator individual Topic managed tandem Topic Leaders: Johan Van der Lei, Erasmus Medical Center academic EMIF-Platform leader Nigel Hughes, Janssen Pharmaceutica EFPIA EMIF-Platform leader Pieter Jelle Visser, VU University Medical Center academic EMIF-AD leader Johannes Streffer, Janssen Pharmaceutica EFPIA EMIF-AD leader Ulf Smith, University Gothenburg academic EMIF-Metabolic leader Dawn Waterworth, GlaxoSmithKline EFPIA EMIF-Metabolic Leader management board overall project level, Operations Team,Programme Board General Assembly responsible dealing day-to-day operations, cross-Topical collaboration defining strategic focus EMIF. individual Topic level, Topic-specific governance defined ensure efficient management Topics. Project management office Dedicated project management support project whole individual Topics provided partner Janssen Pharmaceutica, Synapse Research Management Partners, Concentris GmbH GlaxoSmithKline. Project Advisory Boards EMIF project receives advice strategic focus outcome via three independent advisory boards. Ethical Advisory Board (EAB) EAB providing advice thesetting EMIFs appropriate governance structure addressing ethical, legal, privacy aspect pertaining re-use human health data within EMIF project. EMIF EAB currently ha 6 members: Prof. Luciano Floridi, Professor Philosophy Ethics Information, Oxford Internet Institute, University Oxford Turing Faculty Fellow, Alan Turing Institute, London (chair EMIF EAB) Prof. Effy Vayena, Professor Health Policy, University Zrich Prof. Burkhard Schfer, Professor Computational Legal Theory, University Edinburgh Director SCRIPT Centre IP law Prof. ChristophLtge, holder Peter Lscher Chair Business Ethics, Technical University Munich Prof. Peggy Valcke, Professor ICT medium law, KU Leuven Prof. Ugo Pagallo, Professor Jurisprudence Faculty Law, University Turin Check detailed description EABs responsibility member PDF version summary overview EABs responsibility short bios member Senior Industry Board (SIB) SIBserves ultimate escalation point upon request provide strategic direction EMIF. board composed senior leader participating EFPIA companies. Scientific Advisory Board (SAB) Three SABs set provide advice individual Topics regarding scientific result overall course. SAB composed expert nominated public private partner involved specific Topics. content Copyright EMIF, right Reserved. Last update 07-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation PUBLICATIONS 2018 LINKTOPICTITLEREFERENCEAUTHOR(S)DATE ADAge dependency risk factor cognitive declineBMC Geriatrics 2018 18:187Legdeur N, Heymans MW, Comijs HC, Huisman M, Maier AB, Visser PJ2018-07-01 ADThe EMIF-AD PreclinAD study: Study Design Baseline Cohort OverviewAlzheimers Res Ther. 2018 Aug 4;10(1):75Konijnenberg E, Carter SF, Ten Kate M, den Braber A, Tomassen J, Amadi C et al.2018-06-30 ADCapturing Alzheimers disease pathological cascadeLancet Neurol. 2018 Mar;17(3):199-200Tijms BM, Visser PJ2018-06-30 ADAmyloid-, Tau, Cognition Cognitively Normal Older Individuals: Examining Necessity Adjust Biomarker Status Normative DataFront Aging Neurosci. 2018 Jun 25;10:193Bos I, Vos SJ, Jansen WJ, Vandenberghe R, Gabel S, Estanga et al.2018-06-25 ADInter-laboratory Proficiency Processing scheme CSF aliquoting: Implementation assessment based biomarkers Alzheimers DiseaseAlzheimer's Research & Therapy201810:87Lewczuk P, Gaignaux A, Kofanova O, Ermann N, Betsou F, Brandner et al.2018-08-28 ADThe EMIF-AD Multimodal Biomarker Discovery study: design, method cohort characteristicsAlzheimers Res Ther. 2018 Jul 6;10(1):64Bos I, Vos SJ, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G et al.2018-07-06 ADMRI predictor amyloid pathology: result EMIF-AD multimodal biomarker discovery studyAlzheimer's Research & Therapy201810:100Ten Kate M, Redolfi A, Peira E, Bos I, Vos SJ, Vandenberghe R et al.2018-06-01 ADCSF non-phosphorylated Tau biomarker discrimination AD CJDAnn Clin Transl Neurol. 2018 Jul; 5(7): 883887Ermann N, Lewczuk P, Schimetz M, Lange P, Knipper T, Goebel et al.2018-05-26 ADDiagnostic value cerebrospinal fluid tau, neurofilament, progranulin definite frontotemporal lobar degenerationAlzheimers Res Ther. 2018 Mar 20;10(1):31Goossens J, Bjerke M, Van Mossevelde S, Van den Bossche T, Goeman J, De Vil B et al.2018-03-20 ADWhite paper Society CSF Analysis Clinical Neurochemistry: Overcoming barrier biomarker development clinical translationAlzheimers Res Ther. 2018 Mar 15;10(1):30Teunissen CE, Otto M, Engelborghs S, Herukka SK, Lehmann S, Lewczuk P et al.2018-03-15 ADNeurogranin Cerebrospinal Fluid Biomarker Alzheimer Disease: Assay Comparison StudyClin Chem. 2018 Jun;64(6):927-937Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, van der Flier WM2018-03-01 ADAdded Diagnostic Value Cerebrospinal Fluid Biomarkers Differential Dementia Diagnosis Autopsy-Confirmed CohortJ Alzheimers Dis. 2018;63(1):373-381Niemantsverdriet E, Feyen BFE, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Bjerke M, Engelborghs S2018-02-02 ADLong Non-Coding RNAs Associated Metabolic Traits Human White Adipose Tissue.EBioMedicine. 2018 Apr;30:248-260Gao H, Kerr A, Jiao H, Hon CC, Rydn M, Dahlman I, Arner P2018-01-01 ADGray matter network disruption amyloid beta cognitively normal adultsFront Aging Neurosci. 2018 Mar 15;10:67Ten Kate M, Visser PJ, Bakardjian H, Barkhof F, Sikkes SAM, van der Flier WM et al.2018-01-01 ADPlasma neurofilament light potential biomarker neurodegeneration Alzheimer's diseaseAlzheimers Res Ther. 2018 Jul 28;10(1):71Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P et al.2018-07-28 ADAmyloid oligomers (AOs) Alzheimer's diseaseJ Neural Transm (Vienna). 2018 Feb;125(2):177-191Mroczko B, Groblewska M, Litman-Zawadzka A, Kornhuber J, Lewczuk P2018-02-01 ADA Specific Reduction A1-42 vs. Universal Loss Peptides CSF Differentiates Alzheimer's Disease Meningitis Multiple Sclerosis.Front Aging Neurosci. 2018 May 24;10:152Spitzer P, Lang R, Oberstein TJ, Lewczuk P, Ermann N, Huttner HB, Masouris I, Kornhuber J, Kdel U, Maler JM2018-05-24 ADWhite matter hyperintensities vascular risk factor monozygotic twinsNeurobiol Aging. 2018 Jun;66:40-48Ten Kate M, Sudre CH, den Braber A, Konijnenberg E, Nivard MG, Cardoso MJ, Scheltens P, Ourselin S, Boomsma DI, Barkhof F, Visser PJ2018-06-01 ADAssociation Cerebral Amyloid- Aggregation Cognitive Functioning Persons Without DementiaJAMA Psychiatry. 2018 Jan 1;75(1):84-95Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk et al.2018-01-01 ADScreening Potential Adipokines Identifies S100A4 Marker Pernicious Adipose Tissue Insulin ResistanceInt J Obes (Lond). 2018 Jan 30Arner P, Petrus P, Esteve D, Boulomi A, Nslund E, Thorell et al.2018-01-30 ADCerebrospinal fluid blood biomarkers neurodegenerative dementias: update Consensus Task Force Biological Markers Psychiatry World Federation Societies Biological PsychiatryWorld J Biol Psychiatry. 2018 Jun;19(4):244-328Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ et al.2018-06-01 ADDementia prevalence incidence federation European Electronic Health Record databases: European Medical Informatics Framework resourceAlzheimers Dement. 2018 Feb;14(2):130-139Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P et al.2018-02-01 ADCellular Receptors Amyloid Oligomers (AOs) Alzheimer's DiseaseInt J Mol Sci. 2018 Jun 27;19(7)Mroczko B, Groblewska M, Litman-Zawadzka A, Kornhuber J, Lewczuk P2018-06-27 ADAmyloid production aggregation preclinical Alzheimers disease - monozygotic twin studyAlzheimers Res Ther. 2018 Aug 4;10(1):75Konijnenberg E, Carter SF, Ten Kate M, den Braber A, Tomassen J, Amadi C et al.2018-08-04 MetabolicGamma-glutamyltranspeptidase fraction obese subject type 2 diabetes: relation insulin sensitivity effect bariatric surgeryObes Surg. 2018 May;28(5):1363-1371Franzini M, Musetti V, Guarino D, Caponi L, Paolicchi A, Emdin M, Ferrannini E, Nannipieri M.2018-05-28 MetabolicElevated Plasma Levels 3-Hydroxyisobutyric Acid Associated Incident Type 2 Diabetes.EBioMedicine. 2018 Jan;27:151-155Mardinoglu A, Gogg S, Lotta LA, Stankov A, Nerstedt A, Boren J et al.2018-01-01 MetabolicSystems biology hepatology: approach applications.Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):365-377Mardinoglu A, Boren J, Smith U, Uhlen M, Nielsen J et al.2018-01-01 PlatformKey Ethical Challenges European Medical Information FrameworkMinds Machines doi.org/10.1007/s11023-018-9467-4Foridi L, Luetge C, Pagallo U, Schefr B, Valcke P, Vayena E et al.2018-07-09 PlatformMONTRA: agile architecture data publishing discoveryComput Methods Programs Biomed. 2018 Jul;160:33-42Silva LB, Trifan A, Oliveria JL2018-07-01 PlatformA methodology fine-grained access control exposing biomedical dataStud Health Technol Inform. 2018;247:561-565Trifan A, van der Lei J, Daz C, Oliveira JL2018-09-01 PlatformReal world data reveal diagnostic gap non-alcoholic fatty liver diseaseBMC Med. 2018; 16: 130Alexander M, Loomis K, Fairburn-Beech J, Van der Lei J, Duarte-Salles T, Prieto-Alhambra et al.2018-02-28 PlatformA modular workflow management frameworkIn Proceedings 11th International Joint Conference Biomedical Engineering Systems Technologies - Volume 5: HEALTHINF, 414-421, 2018Almeida JR, Ribeiro R, Oliveira JL2018-01-19 PlatformA methodology perform semi-automatic distributed EHR database queriesProceedings 11th International Joint Conference Biomedical Engineering Systems Technologies - Volume 5: HEALTHINF, 127-134, 2018Fajarda O, Silva LB, Rijnbeek PR, Van Speybroeck M, Oliveria JL2018-01-19 PlatformA De-Identification Pipeline Ultrasound Medical Images DICOM Format.J Med Syst. 2017 May;41(5):89. doi: 10.1007/s10916-017-0736-1Monteiro E, Costa C, Oliveria JL2018-05-01 PlatformcomoRbidity: R package systematic analysis disease comorbidities.Bioinformatics 2018 Sep 15; 18:32283230Gutirrez-Sacristn A, Bravo A, Giannoula A, Myaer MA, Sanz F, Furlong LI2018-04-20 PlatformIdentifying temporal pattern patient disease trajectory using dynamic time warping: population-based studySci Rep, 2018; 8(1): 4216Giannoula A, Gutierrez Sacristn A, Bravo A, Sanz F, Furlong LI2018-03-09 2017 LINKTOPICTITLEREFERENCEAUTHOR(S)DATE MetabolicHypoinsulinaemic, hypoketotic hypoglycaemia due mosaic genetic activation PI3-kinaseEur J Endocrinol. 2017 Aug; 177(2): 175186Leiter SM, Parker VER, Welters A, Knox R, Rocha N, Clark G et al.2017-08-01 MetabolicMuscle adipose tissue morphology, insulin sensitivity beta-cell function diabetic nondiabetic obese patients: effect bariatric surgerySci Rep. 2017 Aug 21;7(1):9007Camastra S, Vitali A, Anselmino M, Gastaldelli A, Bellini R, Berta R et al.2017-08-21 MetabolicPlasma mannose level associated incident type 2 diabetes cardiovascular diseaseCell Metab. 2017 Aug 1;26(2):281-283Mardinoglu A, Stankov A, Lotta LA, Kuusisto J, Boren J, Blher et al.2017-07-09 MetabolicImproving economics NASH/NAFLD treatment use system biologyDrug Discov Today. 2017 Oct;22(10):1532-1538Bosley J, Boren C, Lee S, Grtli M, Nielsen J, Boren J et al.2017-07-09 MetabolicConstitutive activation AKT2 human lead hypoglycemia without fatty liver metabolic dyslipidemiaJ Clin Endocrinol Metab. 2017 Aug 1;102(8):2914-2921Minic M, Rocha N, Harris J, Groeneveld MP, Leiter S, Wareham N et al.2017-05-23 MetabolicInsulin resistance normal thyroid hormone levels: prospective study metabolomic analysisAm J Physiol Endocrinol Metab. 2017 May 1;312(5):E429-E436Ferrannini E, Iervasi G, Cobb J, Ndreu R, Nannipieri M2017-05-15 MetabolicLongitudinal analysis steroid metabolome obese PCOS girl weight loss.Endocr Connect. 2017 May;6(4):213-224Reinehr T, Kulle A, Rothermel J, Knop-Schmenn C, Lass N, Bosse C, Holterhus PM2017-04-03 ADThe frequency influence dementia risk factor prodromal Alzheimer's diseaseNeurobiol Aging. 2017 Aug;56:33-40Bos I, Vos SJ, Frlich L, Kornhuber J, Wiltfang J, Maier W et al.2017-08-01 ADDoes genetic risk help predict amyloid burden non-demented population? Bayesian approachbioRxiv doi.org/10.1101/174995Voyle N, Jansen W, Keohane A, Patel H, Folarin A, Newhouse et al.2017-08-01 ADStrategic roadmap early diagnosis Alzheimers disease based biomarkersLancet Neurol. 2017 Aug;16(8):661-676Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K et al.2017-08-01 ADAmyloid-independent atrophy pattern predict time progression dementia MCIAlzheimers Res Ther. 2017 Sep 12;9(1):73Ten Kate M, Barkhof F, Visser PJ, Teunissen CE, Scheltens P, van der Flier WM, Tijms BM2017-09-12 ADCerebrovascular amyloid pathology predementia stages: relationship neurodegeneration cognitive declineAlzheimers Res Ther. 2017 Dec 29;9(1):101Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi et al.2017-12-29 ADClinical validity medial temporal atrophy biomarker Alzheimers disease context structured 5-phase development frameworkNeurobiol Aging. 2017 Apr;52:167-182.e1Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO et al.2017-04-01 ADCognitive functioning individual aged 90 year older withoutdementia: systematic reviewAgeing Res Rev. 2017 Jul;36:42-49Legdeur N, Binnekade TT, Otten RH, Badissi M, Scheltens P, Visser PJ, Maier AB2017-03-08 ADBrain Amyloid Pathology Cognitive Function - Alzheimer Disease Without Dementia?JAMA. 2017;317(22):2285-2287Visser PJ, Tijms B2017-03-01 ADAssociation blood lipid Alzheimers Disease: comprehensive lipidomics analysisAlzheimers Dement. 2017 Feb;13(2):140-151Proitsi P, Kim M, Whiley L, Simmons A, Sattlecker M, Velayudhan L et al.2017-02-13 PlatformReal world big data clinical research drug developmentDrug Discov Today. 2018 Mar;23(3):652-660Singh G, Schulthess D, Hughes N, Vannieuwenhuyse B, Kalra D2017-12-30 PlatformLa Reutilizacin de la Informacin de la Historia Clnica Electrnica para la Investigacin. De la Medicina Traslacional la Medicina de Precisin: el nuevo paradigma "Learning Health System","I+S: Revista de la Sociedad Espaola de Informtica Salud2017124:14-19"Mayer MA.2017-09-01 PlatformGeneral guideline biomedical software developmentF1000Research 2017, 6:273Silva LB, Jimenez RC, Blomberg N, Luis Oliveira J.2017-07-12 PlatformData Integration Sharing Supporting Drug R&DComprehensive Medicinal Chemistry III vol. 1, pp. 436443Sanz F2017-06-13 PlatformThe launch European Institute innovation health data.Journal Medicines Development Sciences, 3(1): 165.Kalra D, Sundgren M, Claerhout B, et al2017-04-01 PlatformUsing Electronic Health Records Assess Depression Cancer ComorbiditiesStud Health Technol Inform. 2017;235:236-240Mayer MA, Gutierrez-Sacristan A, Leis A, De La Pea S, Sanz F, Furlong LI2017-05-01 PlatformNine Princples Semantic HarmonizationAMIA Annu Symp Proc. 2016; 2016: 451459Cunningham JA, Van Speybroeck M, Kalra D, Verbeeck R2017-02-10 MetabolicCephalic phase insulin secretion response meal unrelated family history Type 2 diabetesPLoS One. 2017 Mar 13;12(3):e0173654Eliasson B, Rawshani A, Axelsen M, Hammarstedt A, Smith U.2017-03-13 MetabolicObesity/insulin resistance rather liver fat increase coagulation factor activity expression humansThromb Haemost. 2017 Jan 26;117(2):286-294Lallukka S, Luukkonen PK, Zhou Y, Isokuortti E, Leivonen M, Juuti et al.2017-01-26 ADMitochondrial gene altered blood early Alzheimer's diseaseNeurobiol Aging. 2017 May;53:36-47Lunnon K, Keohane A, Pidsley R, Newhouse S, Riddoch-Contreras J, Thubron EB et al.2017-08-01 ADThe frequency influence dementia risk factor prodromal Alzheimer's disease.Neurobiol Aging. 2017 Aug;56:33-40Bos I, Vos SJ, Frlich L, Kornhuber J, Wiltfang J, Maier W et al.2017-08-01 MetabolicGenome-wide DNA promoter methylation transcriptome analysis human adipose tissue unravels novel candidate gene obesityMol Metab. 2017 Jan; 6(1): 86100Keller M, Hopp L, Liu X, Wohland T, Rohde K, Cancello R et al.2017-01-01 ADFunctional effective whole brain connectivity using magnetoencephalography identify monozygotic twin pairsSci Rep. 2017 Aug 29;7(1):9685Demuru M, Gouw AA, Hillebrand A, Stam CJ, van Dijk BW, Scheltens P et al.2017-01-01 2016 LINKTOPICTITLEREFERENCEAUTHOR(S)DATE MetabolicIntegrated Network Analysis Reveals Association Plasma Mannose Levels Insulin ResistanceCell Metab. 2016 Jul 12;24(1):172-84Lee S, Zhang C, Kilicarslan M, Piening BD, Bjornson E, Hallstrm BM et al.2016-07-12 ADCerebrospinal Fluid A42/40 Corresponds Better A42 Amyloid PET Alzheimer's DiseaseJ Alzheimers Dis. 2017;55(2):813-822Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM2016-11-01 ADComplement Biomarkers predictor disease progression Alzheimers diseaseJ Alzheimers Dis. 2016 Sep 6;54(2):707-16Hakobyan S, Harding K, Aiyaz M, Hye A, Dobson R, Baird A, Liu B, Harris CL, Lovestone S, Morgan BP2016-09-06 PlatformIdentificare casi di diabete tipo 2 una rete di fonti di dati eterogenee la strategia del progetto EMIFNot Ist Super Sanit 2016;29(10)Roberto G, Gini R2016-10-01 MetabolicA systematic review aetiological predictive biomarkers risk developing type 2 diabetesPLoS One. 2016 Oct 27;11(10):e0163721Abbasi A, Sahlqvist AS, Lotta L, Brosnan JM, Vollenweider P, Giabbanelli P et al.2016-10-27 MetabolicInsulin resistance uncoupled dyslipidemia due C-terminal PIK3R1 mutationsJCI Insight. 2016 Oct 20;1(17):e88766Huang-Doran I, Tomlinson P, Payne F, Gast A, Sleigh A, Bottomley W et al.2016-10-20 ADNon-Phosphorylated Tau Potential Biomarker Alzheimers Disease: Analytical Diagnostic CharacterizationJ Alzheimers Dis. 2017;55(1):159-170Lewczuk P, Lelental N, Lachmann I, Holzer M, Flach K, Brandner et al.2016-11-01 PlatformBig Data Technologies Healthcare Needs, opportunity challengesBDVA Valencia Summit White paperTF7 Healthcare Subgroup. Big Data Value Association2016-11-29 MetabolicGenetic Predisposition Impaired Metabolism Branched-Chain Amino Acids Risk Type 2 Diabetes: Mendelian Randomization AnalysisPLoS Med. 2016 Nov 29;13(11):e1002179Lotta LA, Scott RA, Sharp SJ, Burgess S, Luan J, Tillin et al.2016-11-29 ADGenetic risk plasma tau marker amyloid-beta tau burden cerebrospinal fluidJ Alzheimers Dis. 2017; 55(4): 14171427Voyle, N, Patel H, Folarin A, Newhouse S, Johnston C, Visser PJ et al.2016-12-20 MetabolicNon-alcoholic fatty liver disease risk type 2 diabetesBest Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):385-95Lallukka S, Yki-Jrvinen H2016-06-01 PlatformIdentifying Cases Type 2 Diabetes Heterogeneous Data Sources: Strategy EMIF ProjectPLoS ONE 11(8): e0160648.Roberto G, Leal I, Sattar N, Loomis AK, Avillach P, Egger P, et al.2016-08-31 MetabolicHepatic ceramides dissociate steatosis insulin resistance patient non-alcoholic fatty liver diseaseJ Hepatol. 2016 May;64(5):1167-75Luukkonen PK, Zhou Y, Sdevirta S, Leivonen M, Arola J, Orei M, Hytylinen T, Yki-Jrvinen H2016-05-01 MetabolicPhosphorylated IGFBP-1 non-invasive predictor liver fat NAFLDSci Rep. 2016 Apr 19;6:24740Petj EM, Zhou Y, Havana M, Hakkarainen A, Lundbom N, Ihalainen J, Yki-Jrvinen H2016-04-19 PlatformData Safe Havens Trust: Toward Common Understanding Trusted Research Platforms Governing Secure Ethical Health ResearchJMIR Med Inform. 2016 Jun 21;4(2):e22Lea NC, Nicholls J, Dobbs C, Sethi N, Cunningham J, Ainsworth J, Heaven M, Peacock T, Peacock A, Jones K, Laurie G, Kalra D2016-06-21 ADGenetic variation underlying Alzheimer's disease: evidence genome-wide association study beyondLancet Neurol. 2016 Jul;15(8):857-68Cuyvers E, Sleegers K2016-07-15 ADA Decade Cerebrospinal Fluid Biomarkers Alzheimer's Disease BelgiumJ Alzheimers Dis. 2016 Aug 10;54(1):383-95.Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, De Roeck E, De Vil B, Cras P, Martin JJ, De Deyn PP, Bjerke M, Engelborghs S2016-08-10 ADValidation microRNAs Cerebrospinal Fluid Biomarkers Different Forms Dementia Multicenter StudyJ Alzheimers Dis. 2016 Apr 16;52(4):1321-33.Mller M, Kuiperij HB, Versleijen AA, Chiasserini D, Farotti L, Baschieri F, Parnetti L, Struyfs H, De Roeck N, Luyckx J, Engelborghs S, Claassen JA, Verbeek MM2016-05-08 ADsTREM2 cerebrospinal fluid level potential biomarker microglia activity early-stage Alzheimer's disease associate neuronal injury markers.EMBO Mol Med. 2016 May 2;8(5):466-76Surez-Calvet M, Kleinberger G, Araque Caballero M, Brendel M, Rominger A, Alcolea D, Fortea J, Lle A, Blesa R, Gispert JD, Snchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschtz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgrd B, Blennow K, Crispin A, Ewers M, Haass C2016-05-02 MetabolicRisk factor spontaneously self-reported postprandial hypoglycemia bariatric surgeryJ Clin Endocrinol Metab. 2016 Oct;101(10):3600-3607Nannipieri M, Belligoli A, Guarino D, Busetto L, Moriconi D, Fabris R, Mari A, Baldi S, Anselmino M, Foletto M, Vettor R, Ferrannini E2016-06-23 MetabolicAdipose circulating CCL18 level associate metabolic risk factor womenJ Clin Endocrinol Metab. 2016 Jul 26:jc20162390Eriksson Hogling D, Petrus P, Gao H, Bckdahl J, Dahlman I, Laurencikiene J, Acosta J, Ehrlund A, Nslund E, Kulyte A, Mejhert N, Andersson DP, Arner P, Rydn M2016-07-26 MetabolicThe epigenetic signature systemic insulin resistance obese womenDiabetologia. 2016 Nov;59(11):2393-405Arner P, Sahlqvist AS, Sinha I, Xu H, Yao X, Waterworth D, Rajpal D, Loomis AK, Freudenberg JM, Johnson T, Thorell A, Nslund E, Ryden M, Dahlman I2016-08-18 ADGray matter network disruption amyloid beta cognitively normal adultsNeurobiol Aging. 2016 Jan;37:154-60Tijms BM, Kate MT, Wink AM, Visser PJ, Ecay M, Clerigue M, Estanga A, Garcia Sebastian M, Izagirre A, Villanua J, Martinez Lage P, van der Flier WM, Scheltens P, Sanz Arigita E, Barkhof F2016-01-01 ADDiagnostic Impact Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability Alzheimer's DiseaseJ Alzheimers Dis. 2016;51(1):97-106Niemantsverdriet E, Goossens J, Struyfs H, Martin JJ, Goeman J, De Deyn PP, Vanderstichele H, Engelborghs S2016-02-01 ADImpact APOE-e4 family history dementia gray matter atrophy cognitively healthy middle-aged adultsNeurobiol Aging 2016 Feb;38:14-20Ten Kate M, Sanz-Arigita EJ, Tijms BM, Wink AM, Clerique M, Garcia-Sebastian M, Izagirre A, Ecay-Torres M, Estanga A, Villanua J, Vrenken H, Visser PJ, Martinez-Lage P, Barkhof F2016-02-01 PlatformSemantic Knowledge Base Construction Radiology ReportsHealthinf, (Biostec 2016) ISBN 978-989-758-170-0, page 345-352Monteiro E, Sernadela P, Matos S, Costa C, Oliveira JL2016-02-20 ADComparison Different Matrices Potential Quality Control Samples Neurochemical Dementia DiagnosticsJ Alzheimers Dis. 2016 Mar 1;52(1):51-64Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U et al.2016-03-01 2015 LINKTOPICTITLEREFERENCEAUTHOR(S)DATE PlatformPsyGeNET: knowledge platform psychiatric disorder genesBioinformatics. 2015 Sep 15;31(18):3075-7Gutirrez-Sacristn A, Grosdidier S, Valverde O, Torrens M, Bravo , Piero J, Sanz F, Furlong LI2015-09-15 ADAlzheimer's disease - Recent biomarker development relation updated diagnostic criteriaClin Chim Acta 2015 Sep 20;449:3-8Hglund K, Fourier A, Perret-Liaudet A, Zetterberg H, Blennow K, Portelius E2015-09-20 ADValidation Erlangen Score Algorithm prediction development dementia due AD pre-dementia subjectsJ Alzheimers Dis.2015 Sep 9;48(2):433-41Lewczuk P,Kornhuber J,Toledo JB,Trojanowski JQ,Knapik-Czajka M,Peters O,Wiltfang J,Shaw LM2015-09-09 ADAge-stratified prevalence mild cognitive impairment dementia European populations, systematic reviewJ Alzheimers Dis.2015 Sep 9;48(2):355-9Alexander M,Perera G,Ford L,Arrighi HM,Foskett N,Debove C,Novak G,Gordon MF2015-09-09 ADA novel multi-tissue diagnostic healthy ageing determine cognitive health status using blood RNAGenome Biol. 2015; 16(1): 185Sood S,Gallagher IJ, Lunnon K,Rullman E,Keohane A,Crossland H,Phillips BE, Cederholm T,Jensen T,van Loon LJC,Lannfelt L,Kraus WE,Atherton PJ,Howard R, Gustafsson T,Hodges A,Timmons JA2015-09-07 ADBoosting translational research Alzheimer's disease Europe: Innovative Medicine Initiative AD research platformAlzheimers Dement.2015 Sep;11(9):1121-2Vaudano E,Vannieuwenhuyse B,Van Der Geyten S,van der Lei J,Visser PJ,Streffer J,Ritchie C,McHale D,Lovestone S,Hofmann-Apitius M,Truyen L,Goldman M2015-09-01 ADNo evidence suggest use acetylcholinesterase inhibitor confounds result two blood-based biomarker study Alzheimers diseaseJ Alzheimers Dis.2015 Aug 3;47(3):741-50Chiam JT,Lunnon K,Voyle N,Proitsi P,Coppola G,Geschwind D,Nelson S,Johnston C,Soininen H,Kloszewska I,Mecocci P,Tsolaki M,Vellas B,Hodges A,Lovestone S,Newhouse S,Dobson RJ,Kiddle SJ,Sattlecker M2015-08-03 ADBiomarkers Alzheimer's disease: controversial topicLancet Neurol.2015 Aug;14(8):781-3Frisoni GB,Visser PJ2015-08-01 ADGeneralizability disease state index prediction model identifying patient progressing mild cognitive impairment Alzheimer's disease.J Alzheimers Dis.2015;44(1):79-92Hall A,Muoz-Ruiz M,Mattila J,Koikkalainen J,Tsolaki M,Mecocci P,Kloszewska I,Vellas B,Lovestone S,Visser PJ,Ltjonen J,Soininen H;Alzheimer DiseaseNeuroimaging Initiative;AddNeuroMed consortium;DESCRIPA Kuopio L-MCI.2015-07-07 ADBlood protein marker Neocortical Amyloid Burden: candidate study using SOMAscan technologyJ Alzheimers Dis.2015 Jun 26;46(4):947Voyle N,Baker D,Burnham SC,Covin A,Zhang Z,Sangurdekar DP,Tan Hehir CA,Bazenet C,Lovestone S,Kiddle S,Dobson RJ2015-07-01 ADCerebrospinal fluid P-tau181P: biomarker improved differential diagnosisFront Neurol.2015 Jun 17;6:138Struyfs H,Niemantsverdriet E,Goossens J,Fransen E,Martin JJ,De Deyn PP,Engelborghs S2015-06-17 ADPlasma protein biomarkers Alzheimers disease endophenotypes asymptomatic older twins: early cognitive decline regional brain volumesTransl Psychiatry.2015 Jun 16;5:e584Kiddle SJ,Steves CJ,Mehta M,Simmons A,Xu X,Newhouse S,Sattlecker M,Ashton NJ,Bazenet C,Killick R,Adnan J,Westman E,Nelson S,Soininen H,Kloszewska I,Mecocci P,Tsolaki M,Vellas B,Curtis C,Breen G,Williams SC,Lovestone S,Spector TD,Dobson RJ2015-06-16 MetabolicAssociations potentially modifiable risk factor Alzheimers disease: Mendelian randomization studyPLoS Med.2015 Jun 16;12(6):e1001841stergaard SD,Mukherjee S,Sharp SJ,Proitsi P,Lotta LA,Day F,Perry JR,Boehme KL,Walter S,Kauwe JS,Gibbons LE;Alzheimers Disease Genetics Consortium;GERAD1 Consortium;EPIC-InterAct Consortium,Larson EB,Powell JF,Langenberg C,Crane PK,Wareham NJ,Scott RA2015-06-09 ADPrevalence cerebral amyloid pathology person without dementia: meta-analysisJAMA. 2015 May 19; 313(19): 19241938Jansen WJ,Ossenkoppele R,Knol DL,Tijms BM, Scheltens P,Verhey FRJ, Visser PJ, Amyloid Biomarker Study Group2015-05-19 ADTemporal evolution biomarkers cognitive marker asymptomatic, MCI, dementia stage Alzheimer's diseaseAlzheimers Dement.2015 May;11(5):511-22Bertens D,Knol DL,Scheltens P,Visser PJ;Alzheimer's Disease Neuroimaging Initiative2015-05-01 ADImportance impact pre-analytical variable Alzheimers disease biomarker level cerebrospinal fluidClin Chem Apr 2015; 61(5):734-743Le Bastard N, De Deyn PP, Engelborghs S2015-04-13 ADPrevalence prognosis Alzheimers disease mild cognitive impairment stageBrain.2015 May;138(Pt 5):1327-38Vos SJ,Verhey F,Frlich L,Kornhuber J,Wiltfang J,Maier W,Peters O,Rther E,Nobili F,Morbelli S,Frisoni GB,Drzezga A,Didic M,van Berckel BN,Simmons A,Soininen H,Kloszewska I,Mecocci P,Tsolaki M,Vellas B,Lovestone S,Muscio C,Herukka SK,Salmon E,Bastin C,Wallin A,Nordlund A,de Mendona A,Silva D,Santana I,Lemos R,Engelborghs S,Van der Mussele S;Alzheimers Disease Neuroimaging Initiative,Freund-Levi Y,Wallin K,Hampel H,van der Flier W,Scheltens P,Visser PJ2015-02-18 MetabolicAdipose Tissue Morphology Predicts Improved Insulin Sensitivity Following Moderate Weight LossInt J Obes (Lond).2015 Jun;39(6):893-8Eriksson-Hogling D,Andersson DP,Bckdahl J,Hoffstedt J,Rssner S,Thorell A,Arner E,Arner P,Rydn M2015-02-10 ADLinking genetics brain change Alzheimers disease: sparse whole genome association scan regional MRI volume ADNI AddNeuroMed cohortsJ Alzheimers Dis.2015;45(3):851-64Khondoker M,Newhouse S,Westman E,Muehlboeck JS,Mecocci P,Vellas B,Tsolaki M,Kloszewska I,Soininen H,Lovestone S,Dobson R,Simmons A;AddNeuroMed consortium;Alzheimer's Disease Neuroimaging Initiative2015-02-03 ADAn Integrated Workflow Multiplex CSF Proteomics Peptidomics-Identification Candidate Cerebrospinal Fluid Biomarkers Alzheimer's DiseaseJ Proteome Res.2015 Feb 6;14(2):654-63Hltt M,Minthon L,Hansson O,Holmn-Larsson J,Pike I,Ward M,Kuhn K,Retschi U,Zetterberg H,Blennow K,Gobom J2015-02-01 ADTDP-43 possible biomarker frontotemporal lobar degeneration: systematic review existing antibodiesActa Neuropathol Commun.2015 Apr 1;3:15Goossens J,Vanmechelen E,Trojanowski JQ,Lee VM,Van Broeckhoven C,van der Zee J,Engelborghs S2015-02-01 ADOverdiagnosing vascular dementia using structural brain imaging dementia work-upJ Alzheimers Dis.2015;45(4):1039-43Niemantsverdriet E,Feyen BF,Le Bastard N,Martin JJ,Goeman J,De Deyn PP,Engelborghs S2015-01-15 ADPlasma lipidomics analysis find long chain cholesteryl ester associated Alzheimers diseaseTransl Psychiatry.2015 Jan 13;5:e494Proitsi P,Kim M,Whiley L,Pritchard M,Leung R,Soininen H,Kloszewska I,Mecocci P,Tsolaki M,Vellas B,Sham P,Lovestone S,Powell JF,Dobson RJ,Legido-Quigley C2015-01-13 ADDiagnostic accuracy CSF amyloid- isoforms early differential dementia diagnosisJ Alzheimers Dis.2015;45(3):813-22Struyfs H,Van Broeck B,Timmers M,Fransen E,Sleegers K,Van Broeckhoven C,De Deyn PP,Streffer JR,Mercken M,Engelborghs S2015-01-01 PlatformReuse EHRs Support Clinical Research Hospital ReferenceStud Health Technol Inform.2015;210:224-6Mayer MA,Furlong LI,Torre P,Planas I,Cots F,Izquierdo E,Portabella J,Rovira J,Gutierrez-Sacristan A,Sanz F2015-01-01 ADBlood protein predictor brain amyloid enrichment clinical trials?Alzheimers & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 4860Ashton NJ, Kiddle SJ, Graf J, Ward M, Baird AL, Hye A, Westwood S, Wonga KV, Dobson RJ, Rabinovici GD, Miller BL, Rosen HJ, Torres A, Zhang Z, Thurfjell L, Covini A, Tan Hehir C, Baker D, Bazenet C, Lovestone S, behalf AIBL Research Group2015-03-01 MetabolicCirculating triacylglycerol signature insulin sensitivity NAFLD associated E167K variant TM6SF2J Hepatol 2015 Mar; 62(3):657-63Zhou Y, Llaurad G, Oresic M, Hytylinen T, Orho-Melander M, Yki-Jrvinen H2015-03-01 ADLongitudinal protein change blood plasma associated rate cognitive decline Alzheimer's diseaseJ Alzheimers Dis.2015;49(4):1105-14Sattlecker M, Khondoker M, Proitsi P, Williams S, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Dobson RJ2015-11-23 MetabolicAdipose tissue fatty acid chain length mono-unsaturation increase obesity insulin resistanceSci Rep 2015 Dec 17;5:18366Yew Tan C, Virtue S, Murfitt S, Robert LD, Phua YH, Dale M, Griffin JL, Tinahones F, Scherer PE, Vidal-Puig A2015-12-17 MetabolicBody mass index risk non-alcoholic fatty liver disease: Two electronic health record prospective studiesJ Clin Endocrinol Metab 2016 Mar;101(3):945-52Loomis AK, Kabadi S, Preiss D, Hyde C, Bonato V, St Louis M, Desai J, Gill JM, Welsh P, Waterworth D, Sattar N2015-12-16 MetabolicDefinitions Metabolic Health Risk Future Type 2 Diabetes BMI categories: Systematic Review Network Meta-AnalysisDiabetes Care 2015 Nov;38(11):2177-87Lotta LA, Abbasi A, Sharp SJ, Sahlqvsit AS, Waterworth D, Brosnan JM, Scott RA, Langenberg C, Wareham NJ2015-11-01 MetabolicEvidence causal association hyperinsulinaemia endometrial cancer: Mendelian randomization analysisJ Natl Cancer Inst 2015 Jul 1;107(9): pii: djv178Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, Barker A, Australian National Endometrial Cancer Study Group (ANECS), Perry JR, Attia J, Dunning AM, Easton DF, Holliday E, Lott LA, O'Mara T, McEvoy M, Pharoah PD, Scott RJ, Spurdle AB, Langenberg C, Wareham NJ, Scott RA2015-07-01 ADAlzheimer's disease: report 7th Kuopio Azheimer symposiumNeurodegener Dis Manag 2015 Oct;5(5):379-82Haapasalo A, Pikkarainen M, Soininen H2015-10-29 ADA Pathway Based Classification Method Analyzing Gene Expression Alzheimer's Disease DiagnosisJ Alzheimers Dis 2015 Oct 15;49(3):659-69Voyle N, Keohane A, Newhouse S, Lunnon K, Johnston C, Soininen H Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Hodges A, Kiddle S, Dobson RJ2015-10-15 MetabolicType 2 diabetes migrant South Asians: mechanisms, mitigation managementLancet Diabetes Endocrinol 2015 Dec;3(12):1004-16Sattar N, Gill JM2015-12-01 MetabolicExtensive weight loss reveals distinct gene expression change human subcutaneous visceral adipose tissueSci Rep 2015 Oct 5;5:14841Mardinoglu A, Heiker JT, Grtner D, Bjrnson E, Schn MR, Flehmig G, Klting N, Krohn K, Fasshauer M, Stumvoll M, Nielsen J, Blher M2015-10-05 PlatformChallenges opportunity exploring patient-level dataBiomed Res Int 2015;2015:150435Lopes P, Bastio Silva L, Oliveira JL2015-10-04 MetabolicThe UK10K project identifies rare variant health diseaseNature 2015 Oct 1;526(7571):82-90UK10K Consortium, Walter K, Min JL, Huang J, Crooks L, Memari Y, McCarthy S, Perry JR, Xu C, Futema M, Lawson D, Iotchkova V, Schiffels S, Hendricks AE, Danecek P, Li R, Floyd J, Wain LV, Barroso I, Humphries SE, Hurles ME, Zeggini E, Barrett JC, Plagnol V, Richards JB, Greenwood CM, Timpson NJ, Durbin R, Soranzo N2015-10-01 ADThe genetic landscape Alzheimer's disease: clinical implication perspectivesGenet Med 2015 Aug 27Van Cauwenberghe C, Van Broeckhoven C, Sleegers K2015-08-27 MetabolicThe epigenetic signature subcutaneous fat linked altered expression gene implicated lipid metabolism obese womenClin Epigenetics 2015 Sep 8;7(1):93Arner P, Sinha I, Thorell A, Rydn M, Dahlman-Wright K, Dahlman I2015-09-08 MetabolicTyrosine associated insulin resistance longitudinal metabolomic profiling obese childrenJ Diabetes Res 2016;2016Hellmuth C, Kirchberg FF, Lass N, Harder U, Peissner W, Koletzko B, Reinehr T2015-09-06 ADCurrent development dementia risk prediction modelling: updated systematic reviewPLoS One 2015 Sep 3;10(9):2136181Tang EY, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, Dufouil C, Brayne C, Robinson L, Launer LJ, Stephan BC2015-09-03 PlatformCaf Variome: General-Purpose Software Making Genotype-Phenotype Data Discoverable Restricted Open Access ContextsHum Mutat 2015 Oct;36(10):957-64Lancaster O, Beck T, Atlan D, Swertz M, Thangavelu D, Veal C, Dalgleish R, Brookes AJ2015-08-25 PlatformArchitecture summarize patient-level data across border countriesStud Health Technol Inform 2015;216:687-90Bastio Silva LA, Das C, van der Lei J, Oliveira JL2015-08-19 ADBlood metabolite marker neocortical amyloid- burden: Discovery enrichment using candidate proteinsTransl Psychiatry 2016 Jan 26;6:e719Voyle N, Kim M, Proitsi P, Ashton NJ, Baird AL, Bazenet C, Hye A, Westwood S, Chung R, Ward M, Rabinovici GD, Lovestone S, Breen G, Legido-Quigley C, Dobson RJ, Kiddle SJ2015-08-18 ADC-terminal neurogranin increased cerebrospinal fluid unchanged plasma Alzheimer's diseaseAlzheimers Dement 2015 Dec;11(12):1461-9De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, Andreasson U, De Surgeloose D, Hernalsteen D, Sleegers K, Robberecht C, Van Broeckhoven C, Zetterberg H, Blennow K, Engelborghs S, Vanmechelen E2015-12-01 ADPrevalence Amyloid PET Positivity Dementia Syndromes: Meta-AnalysisJAMA 2015 May 19;313(19):1939-49Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ, Amyloid PET Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jaqust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Snchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chtelat G, Lleo A, Blesa R, Fortea J, Madasen K, Rodrigue KM, Brooks DJ2015-05-19 MetabolicThe fat cell epigenetic signature post-obese woman characterized global hypomethylation differential DNA methylation adipogenesis genesInt J Obes (Lond) 2015 Jun;39(6):910-9Dahlman I, Sinha I, Gao H, Brodin D, Thorell A, Rydn M, Andersson DO, Henriksson J, Perfilyev A, Ling C, Dahlman-Wright K, Arner P2015-03-18 ADAlzheimer's disease cerebrospinal fluid biomarker cognitively normal subjectsBrain 2015 Sep;138(Pt9):2701-15Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argils JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens O, Blennow K, Shaw LM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative2015-07-28 ADDiffusion kurtosis imaging: biomarker early diagnosis Alzheimers disease?J Alzheimers Dis.2015; 48(4):937-48Struyfs H, Van Hecke W, Veraart J, Sijbers J, Slaets S, De Belder M, Wuyts L, Peters B, Sleegers K, Robberecht C, Van Broeckhoven C, De Belder F, Parizel PM, Engelborghs S2015-10-27 2014 LINKTOPICTITLEREFERENCEAUTHOR(S)DATE ADA 22-SNP Alzheimer risk score correlate family history, onset age CSF A42Alzheimers Dement.2015 Jun 15. pii: S1552-5260(15)00191-0Sleegers,Bettens,De Roeck,Van Cauwenberghe,Cuyvers,Verheijen J,Struyfs H,Van Dongen J,Vermeulen S,Engelborghs S,Vandenbulcke M,Vandenberghe R,De Deyn PP,Van Broeckhoven C;BELNEU consortium2014-12-26 ADDiagnostic value MIBG cardiac scintigraphy differential dementia diagnosisInt J Geriatr Psychiatry. 2015 Aug;30(8):864-9Slaets S, Van Acker F, Versijpt J, Hauth L, Goeman J, Martin JJ, De Deyn PP, Engelborghs S2014-11-03 MetabolicFamily history type 2 diabetes increase risk obesity complications: type 2 diabetes disease inappropriate lipid storage?J Intern Med.2015 May;277(5):540-51Cederberg H,Stanckov A,Kuusisto J,Laakso M,Smith U2014-01-09 MetabolicType 2 diabetes disease ectopic fat?BMC Med. 2014 Aug 26;12:123Sattar N, Gill JM2014-08-26 ADTemporal evolution biomarkers cognitive marker asymptomatic, MCI, dementia stage Alzheimer's diseaseAlzheimers Dement. 2015 May;11(5):511-22Bertens D, Knol DL, Scheltens P, Visser PJ; Alzheimer's Disease Neuroimaging Initiative2014-08-20 ADCirculating Proteomic Signatures Chronological AgeJ Gerontol Biol Sci Med Sci.2015 Jul;70(7):809-16Menni C,Kiddle SJ,Mangino M,Viuela A,Psatha M,Steves C,Sattlecker M,Buil A,Newhouse S,Nelson S,Williams S,Voyle N,Soininen H,Kloszewska I,Mecocci P,Tsolaki M,Vellas B,Lovestone S,Spector TD,Dobson R,Valdes AM2014-08-14 MetabolicHypomorphism human NSMCE2 linked primordial dwarfism insulin resistanceJ Clin Invest.2014 Sep;124(9):4028-38Payne F,Colnaghi R,Rocha N,Seth A,Harris J,Carpenter G,Bottomley WE,Wheeler E,Wong S,Saudek V,Savage D,O'Rahilly S,Carel JC,Barroso I,O'Driscoll M,Semple R2014-08-08 ADDepression mild cognitive impairment associated progression Alzheimer's disease: longitudinal studyJ Alzheimers Dis. 2014;42(4):1239-50Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Marin P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S2014-07-07 ADPlasma protein predict conversion dementia prodromal diseaseAlzheimers Dement.2014 Nov;10(6):799-807Hye A,Riddoch-Contreras J,Baird AL,Ashton NJ,Bazenet C,Leung R,Westman E,Simmons A,Dobson R,Sattlecker M,Lupton M,Lunnon K,Keohane A,Ward M,Pike I,Zucht HD,Pepin D,Zheng W,Tunnicliffe A,Richardson J,Gauthier S,Soininen H,Kloszewska I,Mecocci P,Tsolaki M,Vellas B,Lovestone S2014-07-03 MetabolicMutations disrupting Kennedy phosphatidylcholine pathway human congenital lipodystrophy fatty liver diseaseProc Natl Acad Sci U A.2014 Jun 17;111(24):8901-6Payne F,Lim K,Girousse A,Brown RJ,Kory N,Robbins A,Xue Y,Sleigh A,Cochran E,Adams C,Dev Borman A,Russel-Jones D,Gorden P,Semple RK,Saudek V,O'Rahilly S,Walther TC,Barroso I,Savage DB2014-06-17 PlatformEgas: collaborative interactive document curation platformDatabase (Oxford).2014 Jun 11;2014. pii: bau048Campos D,Loureno J,Matos S,Oliveira JL2014-06-11 ADValidation AD-CSF-index autopsy-confirmed Alzheimer's disease patient healthy controlsJ Alzheimers Dis.2014;41(3):903-9Struyfs H, Molinuevo JL, Martin JJ, De Deyn PP, Engelborghs S2014-04-04 MetabolicChanges serum metabolite profile obese child weight lossEur J Nutr.2015 Mar;54(2):173-81Reinehr T, Wolters B, Knop C, Lass N, Hellmuth C, Harder U, Peissner W, Wahl S, Grallert H, Adamski J, Illig T, Prehn C, Yu Z, Wang-Sattler R, Koletzko B2014-04-17 AD, MetabolicAdvanced glycation end products, dementia diabetesProc Natl Acad Sci U A.2014 Apr 1;111(13):4743-4Lovestone S, Smith U2014-04-01 MetabolicA population-based study prevalence NASH using score validated liver histologyJ Hepatol. 2014 Apr;60(4):839-46Hyysalo J, Mnnist VT, Zhou Y, Arola J, Krj V, Leivonen M, Juuti A, Jaser N, Lallukka S, Kkel P, Venesmaa S, Simonen M, Saltevo J, Moilanen L, Korpi-Hyvalti E, Keinnen-Kiukaanniemi S, Oksa H, Orho-Melander M, Valenti L, Fargion S, Pihlajamki J, Peltonen M, Yki-Jrvinen H2014-04-01 MetabolicCirculating Triacylglycerol Signatures Nonalcoholic Fatty Liver Disease Associated I148M Variant PNPLA3 ObesityDiabetes. 2014 Jan;63(1):312-22Hyysalo J, Gopalacharyulu, Bian H, Hytylinen T, Leivonen M, Jaser N, Juuti A, Honka MJ, Nuutila P, Olkkonen VM, Oresic M, Yki-Jrvinen H2014-01-01 MetabolicAdipose Tissue CIDEA Associated, Independently Weight Variation, Change Insulin Resistance Longitudinal Weight Control Dietary Program Obese IndividualsPLoS One 2014 Jul; 9(7):e98707Monastier E, Djean S, Le Gall C, Saris WH, Langin D, Viguerie N2014-07-01 PlatformMedical imaging archiving: comparison several NoSQL solutionsBHI. 2014, Jun;65-68.LAB Silva, L Beroud, C Costa, JL Oliveira2014-06-01 PlatformNormalizing medical imaging archive dose quality assurance productivity auditingMeMeA. 2014, Jun;1-6.LAB Silva, L Ribeiro, C Costa, JL Oliveira, Santos2014-06-11 PlatformSemantic search DICOM repositories2014 IEEE International Conference Healthcare Informatics (ICHI). 204, Sept 15-17, p238-246.LAB Silva, C Costa, JL Oliveira2014-09-15 2013 LINKTOPICTITLEREFERENCEAUTHOR(S)DATE ADUnresolved question Alzheimer's research - biomarkers help?Biomark Med. 2014;8(1):61-3Zetterberg H2013-12-14 MetabolicPrediction non-alcoholic fatty-liver disease liver fat content serum molecular lipids.Diabetologia. 2013 Oct;56(10):2266-74Oreic M, Hytylinen T, Kotronen A, Gopalacharyulu P, Nygren H, Arola J, Castillo S, Mattila I, Hakkarainen A, Borra RJ, Honka MJ, Verrijken A, Francque S, Iozzo P, Leivonen M, Jaser N, Juuti A, Srensen TI, Nuutila P, Van Gaal L, Yki-Jrvinen H2013-07-04 ADPreclinical Alzheimers disease outcome: longitudinal cohort studyLancet Neurol. 2013 Oct;12(10):957-65Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM2013-01-15 content Copyright EMIF, right Reserved. Last update 04-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation DELIVERABLES Deliverables EXECUTIVE SUMMARYTOPICDELIVERABLEDATE PlatformD15.8 - Final report outreach activities2018-06-30 PlatformD15.7 - Final Business Plan2018-06-30 PlatformD14.12 - EMIF Platform2018-06-30 PlatformD14.11 - System implementation feedback evaluation report 42018-06-30 PlatformD13.6 - Final suite module tool data analysis2018-06-30 PlatformD12.7 - Final report data flow data integration processing linkage2018-06-30 PlatformD12.6 - Final version data extraction software2018-06-30 PlatformD11.6 - Final Report Harmonisation Semantics2018-06-30 PlatformD10.5 - Final version EMIF Code Practice2018-06-30 PlatformD9.5 - Final evaluation result roadmap future development2018-06-30 MetabolicD8.5 - Scientific publication describing use clinical trial population-based study investigate natural history NAFLD2018-06-30 MetabolicD8.4 - Legal Ethical Framework established2018-06-30 MetabolicD8.3 - Evaluation liver function test placebo group existing clinical trial try determine factor influence nature2018-06-30 MetabolicD8.2 - Study report manuscript calibration Framingham Risk score European NAFLD patients2018-06-30 MetabolicD8.1 - Test efficiency respect identification clinical trial subject feasibility recruitment2018-06-30 MetabolicD7.4 - Report describing test algorithm clinical outcome diverse population obese adult children2018-06-30 MetabolicD7.3 - Development algorithm predict clinical outcome obese adult children2018-06-30 MetabolicD7.2 - Protocols EMR data extraction analysis understand risk factor associated metabolic diseases2018-06-30 MetabolicD7.1 - report prevalence overlap obesity four endpoint interest real world setting2018-06-30 MetabolicD6.7 - Report describing association potentially causal biomarkers clinical outcome large-scale case-cohort studies2018-06-30 MetabolicD6.6 - Report describing causal significance biomarkers associated metabolic consequence obesity2018-06-30 MetabolicD6.5 - Completion report describing association 6 novel biomarkers emerging WP5 metabolic consequence obesity2018-06-30 MetabolicD5.4 - Identify potential target drug development diagnostic test meet standard clinical sensitivity specificity criteria2018-06-30 MetabolicD5.3 - Functional assessment novel biomarkers cell models2018-06-30 MetabolicD5.2 - Identify novel biomarkers risk extreme phenotype exhibit adequate sensitivity specificity2018-06-30 ADD4.2 - Screening algorithm tested defined2018-06-30 ADD4.1 - Report cross-validated plasma, genetic, CSF, MRI marker diagnosis predementia AD2018-06-30 ADD3.14 - Report joint study AD-Metabolic2018-06-30 ADD3.13 - 10 Assays biomarkers clinical use2018-06-30 ADD3.12 - Integrative model biomarkers different modalities2018-06-30 ADD3.11 - 2 novel combinatorial MRI marker algorithm prognosis2018-06-30 ADD3.8 - 4 Epigenomic profile associated abnormal AD CSF biomarkers2018-06-30 ADD3.6 - 4 GWAS-identified SNPs abnormal CSF abeta tau hippocampal atrophy2018-06-30 ADD3.4 - 2 Metabolomics based plasma marker diagnosis2018-06-30 ADD3.2 - 4 Proteomic based plasma marker prognosis2018-06-30 ADD3.1 - 4 Proteomic based plasma marker diagnosis2018-06-30 ADD2.6 - Definition extreme phenotype based resilience dementia2018-06-30 ADD2.2 - Validated criterion presymptomatic AD prodromal AD2018-06-30 ADD1.5 - Cohort cognitively normal subject 2-year follow-up data2018-06-30 ADD1.4 - Cohort cognitively normal subject AD biomarkers baseline data2018-06-30 ADD1.3 - Dataset EHR data linked research cohort data2018-06-30 ADD3.10 -Novel combinatorial MRI marker algorithm diagnosis2016-12-31 PlatformD9.4 -Second framework evaluation result requirement v32016-12-31 PlatformD10.4 -First draft EMIF Ethical Code Practice2016-12-31 PlatformD11.5 -Second version harmonised information model associated terminology mapping2016-12-31 PlatformD14.9 - System implementation feedback evaluation report, iteration 32016-12-31 PlatformD14.10 -EMIF Platform, version 42016-12-31 PlatformD15.6 -Update Business Plan - February 20172016-12-31 PMOD16.16 -Technical Financial Annual Reports #42016-12-31 ADD3.3 -2 Proteomic based CSF marker prognosis2016-12-31 ADD1.2 - Private Remote Research database environment pooled data research cohorts2015-06-30 ADD2.1 - Summary statistic cohort included2015-12-31 ADD2.2 - Validated criterion presymptomatic AD prodromal AD2015-12-31 ADD2.3 - Definition extreme phenotype based cognitive decline2015-12-31 ADD2.4 - Prediction model cognitive decline2015-12-31 ADD2.5 - Definition extreme phenotype based AD biomarkers2015-12-31 ADD1.1 - Report overview available data sources2013-12-31 MetabolicD5.1 - Establishing functional datawarehousing management2013-12-31 MetabolicD6.1 - Analytical framework investigate metabolic predictor complication obesity2013-12-31 MetabolicD6.2 - report describing systematic review candidate biomarkers prediction metabolic consequence obesity2014-06-30 MetabolicD6.8 - Investigation causal nature association obesity selected obesity-related complications2014-12-31 MetabolicD6.3 - report describing association 6 candidate biomarkers metabolic trait 20 000 participant well-phenotyped metabolically phenotyped studies2015-12-31 MetabolicD6.4 - report describing association metabolomic profile metabolic complication obesity 20 000 participant well-phenotyped metabolically phenotyped studies2015-12-31 PlatformD9.2 - Platform requirement v1 evaluation plan2013-12-31 PlatformD10.3 - Full database fingerprinting2013-12-31 PlatformD11.2 - First version common data model associated terminology mapping2013-12-31 PlatformD12.1 - Data extraction software v12013-12-31 PlatformD14.2 - data management solution vertical projects, version 12013-12-31 PlatformD14.3 - EMIF-Platform, version 12013-12-31 PlatformD15.1 - Report business model data exploitation biosciences2013-12-31 PlatformD14.4 - System implementation feedback evaluation report, iteration 12014-04-30 PlatformD11.3 - Extended specification semantic framework reference2014-06-30 PlatformD13.1 - Evaluation technology tool available data analysis visualization2014-06-30 PlatformD9.1 - Initial requirement set2013-02-28 PlatformD15.2 - Market analysis: usage model data source characterization2014-08-31 PlatformD9.3 - Interim framework evaluation result requirement v22014-12-31 PlatformD12.2 - Data extraction software v22014-12-31 PlatformD12.3 - Interim report primary data flows, benchmarking quality analyses2014-12-31 PlatformD13.2 - Data analysis tool vertical project v12014-12-31 PlatformD14.5 - data management solution vertical projects, v22014-12-31 PlatformD14.6 - EMIF-Platform, version 22014-12-31 PlatformD15.3 - Initial business model description2014-12-31 PlatformD11.4 - Second version common data model associated terminology mapping2014-12-31 PlatformD15.4 - First report outreach activities: leveraging related initiatives, contact external data source key stakeholders2015-04-30 PlatformD10.1 - Initial database fingerprinting2013-03-31 PlatformD13.3 - Data analysis visualization tools, including workflow linkage omics data v12015-06-30 PlatformD14.7 - First EMIF-Platform architecture stack2015-08-31 PlatformD11.4 - First complete version harmonised information model associated terminology mapping2015-12-31 PlatformD12.4 - Interim report data linkage2015-12-31 PlatformD12.5 - Interim report specialised data extraction, benchmarking, aggregation processing2015-12-31 PlatformD13.4 - Data analysis tool vertical project v22015-12-31 PlatformD14.8 - EMIF-Platform, version 32015-12-31 PlatformD15.5 - First draft business plan2015-12-31 PlatformD10.2 - First report federation procedures, ethical legal issues2013-06-30 PlatformD11.1 - Initial specification semantic framework reference2013-06-30 PlatformD14.1 - First report EMIF-Platform desing architecture including specification privacy protection tool services2013-06-30 PlatformD13.5 - Data analysis visualisation tools, including workflow linkage omics data v22016-10-31 PMOD16.1 - Operational portal allow internal team information dissemination, team collaboration, team document storage2013-01-31 PMOD16.12 - Technical financial annual report #12013-12-31 PMOD16.11 - Updated project risk plan WP1-152014-12-31 PMOD16.13 - Technical financial annual report #22014-12-31 PMOD16.2 - Templates dissemination materials: logo design, ppt poster templates, newsletter formats2013-03-31 PMOD16.14 - Interim assessment project2015-08-31 PMOD16.15 - Technical financial annual report #32015-12-31 PMOD16.4 - Communication plan2013-06-30 PMOD16.5 - Project handbook2013-06-30 PMOD16.6 - Guidance document EMIF scientific publications2013-06-30 PMOD16.9 - Operational website internal use external dissemination2013-06-30 PMOD16.10 - Detailed project risk plan WP1-152013-06-30 content Copyright EMIF, right Reserved. Last update 04-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation EMIF NEWSLETTER (MARCH 2017) March 2017 Use button jump article issue. Subscribe Newsletter, please complete . MARCH 2017 01 Enduring Success EMIF: Platform FAIR Data Collaboration EMIF AD-MET Joint GA Meeting, Budapest 2016 KEY POINTS success EMIF prof need findable, accessible, useful data continues grow EMIF IMI created model effectively address need effective data collaboration impact EMIF IMI far reaching, highlight need kind initiative CONTRIBUTORS SIMON lovestoneProfessor Translational Neuroscience, Oxford University, Overall joint program lead EMIF BART VannieuwenhuyseSenior Director RMEDS (Real World Evidence, Medical Affairs, Established Products, Statistics) Quantitative Sciences Janssen, Coordinator overall EMIF project Since IMI began 2008, ha funded many successful program improve healthcare across EU, EMIF ha exception. accomplishment made EMIF, especially , , , produced proven model collaboration data management medical research. so, EMIF allowing research happen speed scale wa previously possible, say Bart Vannieuwenhuyse, Coordinator overall EMIF project, Senior Director RMEDS Qualitative Sciences Janssen. continue progress, EMIF IMI need support. Continuing Need Usable Data 1A Simon Lovestone, Professor Translational Neuroscience Oxford University, overall joint program lead EMIF, reveals one thing EMIF attempting resolve observation make science, vast amount data underutilized. Technology ha enabled u create store mountain data, finding utilizing tends either impossible impractical. data exists two forms. First, electronic health record (EHR) routine patient care, provide huge sample size otherwise unattainable traditional research, also in-depth observational data collected experience individual patients. Second, research data ha already delivered value particular project, could potentially re-used number projects. EMIF designed tackle that, explains Simon. EMIF make data visible provides tool access analyze it. includes multiple portals, including EMIF-AD community, second left FAIR Goal 1B success EMIF initiative ha brought medical research new level making data FAIR (Findable, Accessible, Interpretable, Reusable). demonstrate this, take EMIF-AD community EMIF Catalogue, ha recently made available public. Catalogue, EMIF ha made data Alzheimers Disease visible, ha also created tool efficiently access use data putting common format. ha an, enormously difficult task, Simon admits, Catalogue already demonstrating value. far, program Europe already made use it, including the(DPUK) the(EPAD), another program funded IMI. Take Action 1C impact EMIF IMI even made way across Atlantic Ocean. , United States law enacted President Obama December 2016, cite IMI successful example emulate. important work made possible EMIF need continue. Although EMIF, itself, finite, provides successful model future collaborative project Europe, world. Contact idea extend IMI EMIFs impact rest 2017, beyond. MARCH 2017 02 Building Bridges: EMIF Encourages Collaboration Metabolic Research Beyond KEY POINTS Collaboration fields, industries, sector ha immensely fruitful Sharing data collaboration expert ha allowed researcher take discovery next level Support collaborative effort IMI continue even EMIF begin wind CONTRIBUTORS ULF smithProfessor, University Gothenburg, Project Lead Metabolic topic DAWN WATERWORTHDirector Genetics, Cardiovascular, Metabolic Dermatology, GSK, EFPIA lead Metabolic topic Regardless field, EMIF ha vehicle researcher come together way previously feasible. effect ha particularly powerful field metabolics, via .Two influential member metabolics community, Ulf Smith, Professor University Gothenburg, Project Lead Metabolic topic, Dawn Waterworth, Director Genetics, Cardiovascular, Metabolic, Dermatology GSK, EFPIA lead Metabolic topic, reveal benefit enhanced level collaboration. Collaboration King 2A meaningful discovery advancement possible researcher dont infrastructure go beyond field. Dawn explains order get full value research, need seek variety perspectives. lesson [learned EMIF] reach outside discipline, says. EMIF ha provided unique opportunity researcher across Europe exactly that. fact, recent recent ha indicated IMI initiative receive among highest citation indexes, involve collaboration author across sectors, industries, nations, disciplines. Ulf explains researcher gained connection endure even beyond EMIF. facilitated, ha actually built connection relations, says. Taking Discoveries Next Level 2B pre-EMIF research setting, scientist dug deep small cohort identified inspiring possibility projects, but, Ulf says, dont get say, yes, look promising limited number individuals. opportunity work people done in-depth research within different infrastructure different populations, extremely rewarding, says. Another rewarding experience truly novel result become possible recent work EMIF-MET. Ulf cite particularly interesting found mannose circulating biomarker insulin resistance obesity-associated complications. could done [this] without different extremely carefully phenotyped cohort collected EMIF Metabolic topic, say Ulf. Whats more, beginning. large follow-up study submitted shortly, identified mannose predicts future type two diabetes cardiovascular disease, adds. 40,000,000 de-identified patient record across Europe available, researcher look development metabolic disease time, focus intervention individual high risk. enables researcher test, validate, translate new idea valuable concept potentially useful area like disease development therapy. EMIF IMI make possible derive new insight research. Whats Next 2C EMIF ha produced important work, which, need maintained, implores Ulf. professional relationship cultivated EMIF continue even EMIF begin wind down. scientist genetics, like Dawn, might wide network within field genetics, EMIF IMI broaden reach, says, adding that, allows better, expansive science end day. collaboration need continue, whether supporting new IMI initiatives, broadening professional networks. Left image: EMIF-Metabolic Project Achievements Take Action 2D Keep contact made within EMIF, continue take advantage networking opportunity push outside field sector. connection make ensure continue press forward science community develop innovation research. Contact collaborate network withinor beyondthe field metabolic disease. MARCH 2017 03 Reuse Reconvening: Data Sharing Networking Alzheimers Disease Research KEY POINTS benefit reusing data EMIF project undeniable Bringing diversity healthcare perspective together ha yielded wonderful unforeseen result tool developed IMI great help, people make happen CONTRIBUTORS PIETER JELLE VISSERAssociate Professor, Maastricht University, VU University Medical Center, Project Lead AD topic JOHANNES STREFFERDirector Experimental Medicine, Janssen, EFPIA lead AD topic Medical researcher Europe looking thing new way thanks EMIFs powerful new infrastructure collaboration. Associate Professor Pieter Jelle Visser Maastricht University VU University Medical Center, Johannes Streffer, Director Experimental Medicine Janssen, leader within Alzheimers disease (AD) topic EMIF, represent collaboration academia industry one core achievement EMIF initiative. insight success shed light path ahead, well. Rewards Reuse 3A new infrastructure collaboration provided EMIF ha already proven valuable tool searching treatment associated AD, especially impact society continues grow. major disorder huge social economic impact, treatment yet, explains Pieter Jelle. lack knowledge make infrastructure created EMIF especially important disorder like AD. allows u reuse data ha already collected, significantly lowering time cost required conduct research. One example 50 cohort (10,000 subjects) worldwide wa conducted recently, took two years. But, Pieter Jelle added, collected 10,000 [subjects] scratch would cost around 25 million Euros, would taken something like 10 years. Left image: EMIF-AD Project Achievements Everyone One Table 3B Another major benefit created EMIF-AD ha getting industry academia one table aligning goals, say Johannes. ha also fostered collaboration different representative Pharma industry, even researcher completely different field would never incentive before. One benefit bringing many party together allows u get know one anothers perspectives. Pieter Jelle explains example: field metabolics often focus metabolic disorder affect obesity mortality, he, person working AD research, interested disorder could affect brain. (left right) Suzanne Craft, Simon Lovestone, Hilkka Soininen, Ulf Smith panel theEMIF AD-MET joint meeting Budapest, March 2016 Take Action 3C Pieter Jelle Johannes passionate one topic particular; work done within EMIF-AD IMI continues. infrastructure technology used connect medical research community Europe ha wonderful collaborative tool, technological platform. Johannes insists that, beyond technology involved EMIF, collaborative spirit ha prevalent need endure. take success EMIF next level, AD research beyond. Keep touch connection youve made EMIF, reach outside current research community develop new relationships. Contact idea working across field sharing data, support AD research. MARCH 2017 04 Human Side Big Data: EMIF-PLAT Paving New Roads Medical Research KEY POINTS Despite initial challenges, EMIF-PLAT proving worth exceeding expectation EMIF-PLAT isnt changing technology, changing society Harmonization possible: data, people CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIF-PLAT, Janssen Pharma R&D JOHAN VAN DER LEIAcademic Coordinator EMIF-PLAT, Professor Erasmus University inception, EMIF Platform () team worked overcome technical societal hurdles. constant evolution refinement, created platform, created new way conceiving whats possible shared data medical science. Already, result work validatingand inspiring. Nigel Hughes, EFPIA Coordinator EMIF-PLAT, Janssen R&D, Johan Van Der Lei, Academic Coordinator EMIF-PLAT Professor Erasmus University, agree human le measurable output among powerful. collaborative spirit brought many great people together EMIF become essential solving challenging healthcare quality life issue time. Building Plane, Flying Plane 4A first decided merge , , PLAT project within EMIF proposal five year ago, task data harmonization wa met degree skepticism. Data wa hand many different people organizations, disparate way storing managing it. tackle that, learning go, building learning, say Nigel. learning ha open source technology help systematize standardize data collection storage. learning ha around value cross-field even cross-project collaboration. fact, EMIF-AD, EMIF-MET, EMIF-PLAT, shouldnt cant exist separate projects, say Nigel. Although independent work sometimes necessary, increasingly, second half EMIF project, decision made based dialogue projects. example, platform wa conceived created time Alzheimers metabolic team expressing needed platform. wa like trying fly plane youre still building it, reveals Nigel. beauty simultaneous process wa EMIF-PLAT team built real people real project need. Left Image: detailed architectural view reveals two paths: population cohort. learn technical aspect EMIF-PLAT, contact , tune next issue EMIF Newsletter. Proven Need 4B One early win EMIF-PLAT wa ability vastly improve speed people identify data sources. systematised, meta-data driven listing data source within EMIF. January 2017, EMIF Data Catalogue wa released beyond EMIF community. le two months, 300 bonafide researcher already signed explore 14 population data source 46 EMIF-AD cohorts. plan coming year, Johan says, expand capability researcher evaluate suitability ultimately conduct study data source collaborators. available bonafide researcher outside EMIF Long Winding Road 4C many ways, bump road building EMIF-PLAT human technological. socio-technical issue! something may heard youve ever spoken Johan. Yes, data one zeroes, end day people health data managed universities, governments, payers. mean access also relationships, laws, intended use data. Ultimately gaining trust, say Nigel, that, people need see something works. Guess What, Works 4D greatest legacy EMIF-PLAT certainly harmonization. already many example harmonizing data vastly improves usability research, partnership Observational Health Data Sciences Informatics () collaboration, EMIF-PLAT also focus human harmonization. powerful tool available overcome pressing human challenges, medical otherwise, one another. EMIF-PLAT already proving whats possible. beginning. Take Action 4E need strive meaningful collaborations. EMIF-PLAT team look forward collaborating project (IMI, IMI2, others), well partner across industries, companies, fields, sectors, whether public private. need continue pushing open source technology open source idea support open science. Instead withholding lesson learned, Nigel Johan want share them. Whether youre architect, bioinformatics expert, ethicist, contact youd like learn social technical aspect EMIF-PLAT, youd like share idea harmonization ensure legacy EMIF-PLAT life on. MARCH 2017 05 Big Data, Big Goals: IMI Projects Lead Way Harnessing Power Big Data KEY POINTS IMI ha already demonstrated value big data several successful project Look new project coming IMI continue work toward goal Despite legal logistical difficulties, value big data undeniable CONTRIBUTORS PIERRE MEULIENExecutive Director Innovative Medicines Initiative Big data analysis hold enormous potential acquiring new actionable medical knowledge. increasing availability database containing medical research data, combined growing analytic capability could lead better treatment improved outcome patients. world largest public-private partnership life sciences, perfectly placed harness potential lay groundwork reuse clinical data Europe. History Success 5A Several IMI project already working towards goal. good example one IMIs older big data projects, , started 2011. connecting electronic health record 11 different hospital across Europe, project created platform help researcher design clinical study recruit patient participate them. platform connect securely anonymized data within multiple hospital electronic health record system clinical data warehouse across Europe, enabling researcher predict number eligible patient candidate clinical trial protocol. also help ass feasibility trial locate relevant hospital site recruiting patients. Another IMI project field , focus improving translation data pre-clinical clinical studies. service project us open source tool, tranSMART, provide access different type biological clinical data well-structured environment. project place special emphasis data cleaning standardization deliver high data quality improve cross-study compatibility. 40 project already benefited services. Among eTRIKSs achievement creation : unique repository contains description IMI project databases. catalogue making easier researcher find information clinical datasets may available reuse. then, course, EMIF, IMI project using power big data solve riddle two big healthcare challenge time: metabolic disorder Alzheimers disease. order improve understanding diseases, EMIF team connecting multitude relevant data source across Europe. process, theyre addressing number data issues, including data standards, semantic interoperability, ethics, data privacy, legal issues. project also developing platform allow access multiple data source done finished may interlink data 50 million adult across Europe. Horizon 5B Looking toward future, new IMI project field starting, part IMIs Big Data Better Outcomes (BD4BO) program launched 2016. program aim facilitate use diverse data source deliver outcome measure treatment meaningful patients, clinicians, regulators, researchers, others. Disease-specific project addressing Alzheimers disease (), blood cancer () already started, project cardiovascular disease launched soon. project look available clinical data multitude sources, disease areas, combine, standardize analyze data obtain relevant outcome measures. Part program also newly launched IMI project called DO->IT. Rather focusing specific disease area, project aim generalize result BD4BO project disease areas. One main deliverable generic, informed consent form template participant clinical trials. language form formulated way allow clinical data reused research purposes. project aim disseminate form among researcher companies, used widely possible. Apart project work issue directly, IMI want instil good data practice projects. Prior starting, project required fill , encourages team think early collecting storing data according good standards. idea, course, ensure data generated IMI project potentially combined data generated elsewhere, analyzed bigger scale. Take Action 5C move increasingly digital environment healthcare, also society, big data become major determinant future medicine shaped. public-private partnership, involving multitude stakeholders, IMI project leading way field, creating framework data across Europe could shared easily. success IMI project field ha potential persuade data holder across Europe legal logistical obstacle clinical data reuse overcome, greater benefit patients. Contact find aboutand get involved inthe continuing effort IMI. content Copyright EMIF, right Reserved. Last update 08-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation EMIF NEWSLETTER (JUNE 2017) June2017 Use button jump article issue. Subscribe Newsletter, please complete . JUNE 2017 01 Power Harmonization: EMIF Enables Large-Scale Analytics Embracing OMOP Common Data Model EMIF currently mapping European data source OMOP CDM extending OHDSI tool . order properly answer biggest research question timeincluding would help u solve mystery Alzheimers disease metabolic diseaseswe need ass large amount data fully transparent reproducible way. Standardization data structure language Common Data Model (CDM) enables unprecedented scale. KEY POINTS Data harmonization process translating data common format common vocabulary enable collaborative research large-scale analytics. European Medical Information Framework (EMIF) ha core objective building information framework consistent re-use available patient-level data support novel research. Observational Health Data Sciences Informatics (OHDSI) collaborative work toward international implementation OMOP Common Data Model (CDM) standardized vocabularies. EMIF currently mapping European data source OMOP CDM, extending OHDSI tool enable large-scale analytics key EMIFs core objectives. CONTRIBUTORS MICHEL Van SpeybroeckDirector Data Sciences Janssen PETER Rijnbeek, PhDAssistant Professor Erasmus University Medical Center JOHAN van der LeiAcademic Coordinator EMIF-PLAT, Professor Erasmus University Medical Center Big Healthcare Data 1A Every moment, countless healthcare data point generated stored digital database across Europe. Analyzing datasets challenge, data structure content vary greatly one healthcare organization next. Data collected different purposes: clinical research, patient care, payer reimbursement, more. mean content level detail varies considerably. Datasets stored different format using different database management systems. Moreover, different code used medical concept across Europe, creates additional challenges. overcome overwhelming barrier performing multi-database study across Europe beyond? EMIF Rises Challenge 1B recognized challenge day one. Standardization wa initially done context specific research question limited set variables. However, EMIF realized approach wa difficult maintain answering research question large scale. substantial upfront standardization effort would necessary scalability. Additionally, study needed performed distributive manner comply governance privacy rule keeping standardized datasets within local infrastructures. shared analytical datasets needed generated using standardized processing pipeline. Odyssey Toward Harmonization 1C EMIF found solution challenge embracing (OHDSI, pronounced Odyssey) model translating data single common structure language. concept known data harmonization (also sometimes called data standardization). representing process data harmonization using OMOP Common Data Model. , public-private partnership originally established US. OMOP project developed initial version , accommodate healthcare data diverse source consistent standardized way. OHDSIs mission improve health, empowering community collaboratively generate evidence promotes better health decision better care. key objective stimulate transparent reproducible research CDM prerequisite. Today, OHDSI international collaborative comprised academics, industry scientists, healthcare providers, regulator come together create apply open-source data analytic solution large network health databases. non-funded entity, supported generosity passion individual member well in-kind contribution organization Columbia University Johnson & Johnson. inspiring spirit global collaboration power OHDSI. EMIF Common Data Model 1d many reasons. OMOP CDM well-adopted model covering 600 million patient life worldwide. code tool open source publicly available, stimulates collaborative tool improvement transparency. Moreover, currently available tool fit naturally EMIFs objective facilitate different level data access. Workflow map EMIF EHR data source OMOP CDM, leveraging OHDSI tool experience. CDM widely used US Asia, beginning scratch surface use Europe. EMIF helping prototype CDM European continent. example, exploring whether level detail European Electronic Health Records (EHR) would lost translated data CDM. peer fellow collaborator OHDSI constantly adjusting CDM vocabulary accommodate type insights. CDM also evolving healthcare evolves. OMOP Common Data Model expands continents, countries, disease areas, CDM expands thanks collaboration OHDSI champion around globe. Calling Data Custodians 1F EMIF want actively support adoption OMOP CDM across Europe. data custodian Europe want participate innovative data network, contact , , learn more. mapping data doe require time commitment, EMIF available help. Additionally, ODHSI website offered free-to-attend OHDSI symposia. Documents best practice converting data OMOP CDM available . clear advantage adopting ODHSI EMIF working on. Thanks multi-disciplinary expertise OHDSI community, quality functionality tool constantly improved. process open source start finish, license ever needed. Perhaps importantly, data privacy concern respected keeping data local. implementing CDM yourself. Even EMIF provide support technical side process, data still kept locally. Youll able maintain privacy database contributing worldwide effort harmonize data. decision map database CDM mean supporting progress reproducible scientific research local, national, international level. Next Steps EMIF 1G EMIF actively mapping nine European data source OMOP CDM OHDSI vocabularies: Denmark (AUH), Italy (ARS, IMS HEALTH LPD, PEDIANET), Spain (IMASIS, SIDIAP), UK (THIN), Estonia (EGCUT), Netherlands (IPCI, PHARMO). EMIF produce scientific paper year evaluates mapping process European datasets formulates suggestion improving CDM vocabularies. Furthermore, EMIF continue effort extending refining OHDSI tool meet objectives. want data analysis unprecedented scale, along fully transparent reproducible research pipelines, need collectively harmonize data structure terminology. OMOP CDM clearly becoming de facto standard electronic health data across world. EMIF recognizes exciting new reality, stakeholder benefit: researchers, organizations, importantly patientswho ultimately center global effort. researcher want explore more, please visit . data custodian interested learning OMOP-CDM data source, contact , , . JUNE 2017 02 Knowledge Comes Responsibility: Harmonizing Cohort Data EMIF-AD European Medical Information Framework Alzheimers Disease (EMIF-AD) Work Package (WP) 1 team members, left right: Pieter Jelle Visser, Stephanie Vos, Isabelle Bos. () researcher Simon Lovestone, Pieter Jelle Visser, Johannes Streffer led team identify potential fluid marker brain amyloid small study cognitively normal people. wanted confirm finding sample 1,000 individuals, didnt resource assemble large cohort de novo. Luckily, one EMIFs objective make possible re-use data instead generating new data single purpose. Electronic Health Record (EHR) data standardized ; however, cohort data, another solution wa necessary. KEY POINTS European Medical Information Framework (EMIF) Catalogue allows user quickly complete new research identifying cohort via EMIF Alzheimers disease (EMIF-AD) community. Analyses large pooled datasets made possible technical team developed idea using knowledge object purpose data harmonization. EMIF-AD team invite data custodian researcher provide metadata cohort share data research question help crack dementia code. CONTRIBUTORS RUDI VerbeeckSenior Manager Janssen R&D ISABELLE BosNeuropsychologist PhD Candidate Maastricht University LUIZA Gabriel-ZeltzerPostdoctoral Researcher Janssen R&D STEPHANIE VosNeuropsychologist Postdoctoral Researcher Maastricht University PIETER Jelle VisserAssociate Professor, Maastricht University, VU University Medical Center, Project Lead AD topic Biomarker Discovery Study 2A Within EMIF-AD, project divided work package (WPs). WP 1 focus definition study population data requirement data collection. Members EMIF-AD WP 1 team (Pieter Jelle Visser, Stephanie Vos, Isabelle Bos) consulted AD community, online community existing cohort maintained EMIFAD. identified 11 suitable cohort participant characteristic researcher looking term age, sex, cognitive status, amyloid biomarkers cerebrospinal fluid (CSF) positron imaging tomography (PET), availability MRI scan fluid sample plasma CSF. EMIF-AD WP 1 team contacted principal investigator cohort interested participate. Contracts set-up allow data-sharing biomarker analysis. Data source owner harmonizedor translatedtheir local variable global set variable data could used study. way, large cohort wa assembled quickly inexpensively. final Biomarker Discovery Study included 1,221 subjects. data combined proteomics, genomics, metabolomics, imaging data single analysis. broad spectrum analysis large cohort subject various cognitive stage provide new insight underlying mechanism facilitate discovery new diagnostic prognostic marker AD. study coordinated Simon Lovestone, Johannes Streffer, Pieter Jelle Visser close collaboration proteomics, metabolomics, transcriptomics, genomics, bioinformatics imaging expert EMIF-AD. Translating Language Science 2B Biomarker Discovery Study analysis large cohort made possible collaboration EMIF-AD researcher EMIF-Platform technical team developed idea using knowledge object purpose data harmonization. knowledge object variable, plus information need order correctly interpret variable means. instance, sex knowledge object included Biomarker Discovery Study, male female common value knowledge object. Diagram envisioning process data harmonization, mapping local knowledge object global knowledge objects. Data source appear left, harmonized data appears right. EMIF-AD researcher gathered data 11 different study assemble EMIF-AD WP3 1000 cohort, different language none used exactly standard recording variables. tried access original data data sources, variable sex might appeared genero geschlecht. obscure variable may difficult interpret impossible translate similar datasets without common reference point. Thats Rudi Verbeeck, Senior Manager Janssen R&D EMIF contributor, belief cohort data custodian play crucial role quest aggregate data. data custodian know variable data source truly represent. Thanks EMIF-Platform team, custodian power define local variable data translated standard set global variables. Knowledge Responsibility 2C knowledge, responsibility, explains Rudi. Data custodian knowledge data, responsible defining local variables. Researchers know point data support research, responsible identifying variable want access. brings together knowledge data custodian knowledge researcher data harmonized large cohort analyzed? Isabelle Bos Stephanie Vos, neuropsychologists researcher Maastricht University, member EMIF-AD WP 1 team. Theyve chosen take responsibility helping data custodian translate local knowledge object global knowledge objects. data custodian dont technical skill map data themselves, data custodian specifies mapping done, EMIF-AD WP 1 team creates code need executed. currently 14 cohort data platform across Europe (Netherlands, UK, Belgium, Spain, Italy, Sweden, France, Greece). total number subject across 14 cohort 3,423, number keep growing. Local knowledge object (LKO) appear left side semantic dependency graph. local knowledge object translated global knowledge object (GKO) using snippet code (represented arrows). Sometimes, one-to-one correlation local knowledge object global knowledge object. times, multiple local knowledge object feed single global knowledge object series standardizing equations. Building Library 2D time, EMIF-Platform continue building library reusable knowledge object snippet code connect them. researcher make request EMIF Catalogue AD community variable havent used before, knowledge object need mapped data custodian support EMIF-AD WP 1 team. Since every research question add library, probability able reuse knowledge object snippet code increase every research question come along. Common Goal 2E order tackle biggest health challenge time, researcher must able conduct efficient cost-effective data analysis large scale. that, necessity. cohort 100 subjects, cant answer complex research questionsbut increase cohort 1,000, may uncover kind exciting result EMIF-AD group collaborator seeing Biomarker Discovery Study. harmonize data, need shared. cohort-derived dataespecially includes biomarkersand would like collaborate, please consider working EMIF-Platform team harmonize data using knowledge objects. Harmonized cohort data could lead breakthrough fight Alzheimers. researcher, explore data source already available AD EHR communities, made publicly available bona fide researcher outside EMIF January 2017. Every day, new people around world join 309 user accessed Data Catalogue work toward research goals. could assemble huge cohort quickly inexpensively, kind study would create? discovery might spearhead? EMIF want know want help make happen. JUNE 2017 03 Introducing Use Case 12: Using Electronic Health Record Data Understand Relationship Dementia Inflammation Oxford University research team exploring link dementia inflammatory diseases. medical science research community pondering relationship dementia inflammatory diseases. Alejo J. Nevado-Holgado Danielle Newby, post-doctoral researcher University Oxford, exploring link depth. found asking: inflammatory diseasesor drug used treat themchange risk dementia later life? compelling research question set stage Use Case 12, project underway within the. KEY POINTS analyzing electronic health record (EHR) data European Medical Information Framework (EMIF) platform, find link inflammation dementia. Use Case 12 utilizing EMIFs visible, accessible, harmonized datasets complete ground-breaking research whether inflammatory disease drug used treat change risk dementia later life. Later 2017, look published information likely assist development therapy treatment dementia. CONTRIBUTORS DANIELLE NEWBYPost-doctoral researcher University Oxford, Data analyst Use Case 12 ALEJO NEVADO-HOLGADOSenior post-doctoral researcher University Oxford, Lead Use Case 12 project SIMON LOVEStoneProfessor Translational Neuroscience University Oxford, Overall joint program lead EMIF Challenges Solutions 3A motivated team Oxford wa curious relationship inflammatory diseases, anti-inflammatory drugs, dementia. saw exiting opportunity work large, real-world, routine care datasets, realized study challenging perform. one thing, large datasets needed analysis. another, research study cohort suffer selection always fully representative. large datasets accessible, Danielle emphasizes, another challenge present itself: tough get consistent datasets due different structure electronic health record (HER) different countries. EMIF provided opportunity overcome problem making datasets visible, , . Use Case 12, Oxford team examining relationship disease inflammation drug used treat inflammatory disorder multiple datasets. work, theyre revealing stronger evidence relationship dementia inflammatory exposures. team ground-breaking research set example others. researcher may excited learn question like posed within Use Case 12 analyzed answered efficiently working EMIF. Start Finish 3B start Use Case 12, team needed good question could potentially answered using EHR data. hypothesis relating inflammation dementia, protocol underwent ethical peer review expert field. next step wa contact data custodian responsible datasets ; able participate joined Use Case 12. team asked data custodian extract variable needed anonymized patient level record database place secure remote research environment. Daniel Prieto-Alhambra, scientific coordinator SIDIAP database, wa enthusiastic contributing SIDIAP database Use Case 12, stating inclusion SIDIAP dataset Use Case 12 offer great opportunity utilize wealth information database help understand important topic. quality control check datasets, local database expert started work. dataset, ran software tool aggregated file dataset, removed outliers, selected sample population based criterion specified original protocol. Thanks seamless collaboration EMIF-Platform team, data dataset stage wa ready statistical analysis. Workflow Use Case 12 Now? 3C Use Case 12 cusp exciting phase: data analysis! Nearly datasets extracted almost ready analyzed. team built clever step process; analyzing one dataset first, run preliminary check help troubleshoot analysis rest datasets. Alejo confirms participating Use Case 12 ha excellent learning experience team come opportunity challenge analysis across multiple real-world datasets. fortunate good help expertise guide u move work forward successfully, Danielle reports. Later 2017, look publication finding datasets Use Case 12. team belief result could lead meaningful advancement treatment Alzheimers disease dementia. Take Action 3D perfect example successful collaboration data sharing among researcher data custodians. idea think could answered using EHR data, progress Use Case 12 give confidence robust analysis possible. would like learn get involved continuing progress Use Case 12, contact collaborate network. welcome ideas, help, expertise anyone within EMIF interested involved dementia research. Danielle, speaking behalf Use Case 12 team, says: want collaborate share knowledge make even greater progress toward ultimate goal: development new therapy treatment dementia. reading determining molecular pathway underlying protective effect non-steroidal anti-inflammatory drug Alzheimers Disease, please see Alejo Simons October 2016 . JUNE 2017 04 Precompetitive Research Multi-Disciplinary Team: Investigation Non-Alcoholic Fatty Liver Disease Recorded Primary Care Databases cross-company team discovered heterogeneity prevalence recorded non-alcoholic fatty liver disease European databases. diverse team come together tackle research question rising epidemic metabolic disorders? Theproject make possible. Non-Alcoholic Fatty Liver Disease Electronic Health Record (NAFLD-EHR) team, subset EMIF-Metabolic. team composed member pharmaceutical industry academia, background ranging epidemiology genetics medicine statistics; member expertise cardiovascular disease hepatology, others deep knowledge healthcare databases. scattered around globe, mainly located Europe, would chance come together without infrastructure EMIF within the. KEY POINTS European Medical Information Framework (EMIF) enables collaboration partner pharmaceutical industry academia. EMIF collaborator conduct precompetitive research multiple European database unified environment. EMIF enables pharmaceutical industry unprecedented access routinely recorded European healthcare data respecting appropriate security ethic provisions. cross-company team discovered heterogeneity prevalence recorded non-alcoholic fatty liver disease European databases, well low detection rate primary care. CONTRIBUTORS MYRIAM ALEXANDERClinical data scientist analyst GlaxoSmithKline NAVEED SATTARProfessor Metabolic Medicine University Glasgow DAWN Waterworth Genetics Director GlaxoSmithKline KATRINA loomisHead Cardiovascular Metabolic Disease Human Genetics Pfizer WILLIAM alazawiSenior lecturer Consultant Hepatology Blizard Institute, Barts London School Medicine JOLYON fairburn-beechData analyst GlaxoSmithKline Motivating Questions 4A Prior collaborating, u wa motivated answer key question epidemiology non-alcoholic fatty liver disease (NAFLD), as: prevalence incidence disease primary care data? NAFLD associated increased risk cardiovascular disease accounting risk factor may potentially confound association? excess risk NAFLD patient experience come developing liver complications, including cirrhosis hepatocellular carcinoma? question remained difficult answer without access large sample patient extensive medical data. Fortunately, opportunity work within EMIF. Unprecedented Access 4B Via EMIF, access unprecedented large-scale database collected routinely primary care system four European countries: UK: Netherlands: Catalonia region Spain: Italy: identified suitable database using EHR community, used support EMIF contact data custodian project partners. Attrition demographic characteristic patient NAFLD four European databases. Harmonizing Data 4C Use Case 10, team developed protocol submitted ethical review body database; upon approval, single finalized protocol wa circulated parties. four database used different terminology system code clinical diagnoses, process data harmonization wa needed enable team create comparable lists. protocol wa translated series data management statistical analysis steps, data wa locally extracted data custodian centrally analyzed remote server. New Level Trust 4D Thanks EMIF, pharma company involved project able accessfor first timean anonymized subset raw data databases. there, company able perform analyses, plumbing depth various databases. ha enabled party experience new level trust efficient reuse routine data benefit bona fide research. First Results 4E analysis data analyst GlaxoSmithKline (GSK) ongoing. late-breaking abstract wa presented incidence prevalence NAFLD. Data available 17.4 million adult 1 year follow-up registration. 135,000 individual diagnosis NAFLD non-alcoholic steatohepatitis (NASH), amounting pooled prevalence 1.7% January 2014. Although relatively low compared prevalence estimate literature 20 30% NAFLD general population, patient characteristic line literature. Incidence recorded NAFLD (per 1,000 person-years) 20042014 four countries, pooled across countries. Point-Prevalence recorded NAFLD (per 100 persons) 20042014 four countries, pooled across countries. Next Steps 4F sample NAFLD patient represents largest NAFLD cohort ever assembled. enable research NAFLD, interest pharmaceutical industry field medicine. team especially excited potential research may answer motivating question mentioned above. want know NAFLD associated increased risk cardiovascular disease accounting risk factor may potentially confound association, also want know excess risk NAFLD patient experience come developing liver complications. Progression NAFLD NASH beyond (source: Decision Resources). youre field metabolics want learn study findings, contact . JUNE 2017 05 Milestone Meeting: EMIF-Platforms 9th Consortium Meeting EMIF-Platform colleague gathered Barcelona May 2223, 2017, 9th Consortium Meeting EMIF-Platform. January 2013, the(IMI), world largest public-private partnership life sciences, began funding landmark initiative. The(EMIF) wa launched ground breaking five-year project develop technical governance solution improve access use health data. 2017 mark EMIFs fifth final year funding IMI. go accomplished far? KEY POINTS exciting 9th Consortium Meeting European Medical Information Framework (EMIF) Platform took placein Barcelona, May 2223, 2017. Important milestone discussed, including technology platform, data harmonization, sustainability, research use cases, expedited research efficiency, publication strategy. EMIF making significant contribution field real world data health research, work remains done final year Innovative Medicines Initiative (IMI) project. CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIF-PLAT, Janssen Pharma R&D past four years, EMIF made considerable progress. developed integrated platform facilitate access diverse medical research data source across Europe. sustainable framework support identification, assessment, use reuse health data medical research. guide development information framework, IMI originally selected two therapeutic area critically important juncture history: Alzheimers disease (EMIF-AD) metabolic disease (EMIF-Metabolic). pressing research topic provided EMIF-Platform clear opportunity support researcher technological tool governance processes. Thanks EMIF-Platform team, researcher EMIF-AD EMIF-Metabolic working address world biggest health challenges. Meeting Minds 5A Since EMIF-AD EMIF-Metabolic leverage framework created EMIF-Platform, one could say EMIF-Platform bedrock EMIF. Thats approximately 50 EMIF colleague met Barcelona 9th Consortium Meeting . May 22 23, 2017, EMIF-Platform team shared milestones, recognized progress, discussed work horizon rest year. Six major theme emerged. Theme 1: Technology Platform 5B first time four-year history EMIF, integrated platform wa presented outline form (see figure 1). evaluating integrated platform rest year, visualization major achievement EMIF. integrated platform allows researcher access , specify parameter data fit research questions, analyze data secure private remote research environment (PRRE). technological development mean researcher able analyze large datasets still respecting data privacy. Figure 1: Integrated EMIF Platform Theme 2: Data Harmonization 5C EMIF-Platform ha helped European continent advance towards data harmonization. continue map population data source (CDM). EMIF-Platform team working hard make sure data custodian colleague comfortable mapping conversion process. EMIF-Platform team also offering support data custodian use (OHDSI) mapping data CDM. Simultaneously, making progress assembling cohort data EMIF-AD. variable translate data local global vocabulariesallow u add AD cohort EMIF Catalogue AD community. knowledge object team similarly support data owner researcher add access relevant cohort data. Theme 3: Sustainability 5D EMIFs goal create sustainable technology governance framework identification, assessment, use reuse health data medical research Europe. Weve spent past four year developing technology governance framework. Now, increasing focus sustainability. weve made progress toward developing potential sustainability model population cohort tracks, much work needed end year. need clear plan implement EMIFs proposed extension first half 2018.. Theme 4: Research Use Cases 5E 9th EMIF-Platform Consortium Meeting, colleague shared progress many use case (see figure 2), come fruition later year. Invaluable insight use case help EMIF better understand research process, well potential challenge researcher data custodian face. Stay tuned use caseslike documented shared. Figure 2: EMIF-Platform Research Use Cases currently running Theme 5: Expediting Research Efficiency 5F Deeper insight research processespecially come bottleneck potential solutionswill enable EMIF manage research efficiently. Insights current use case proposed study allow u pressure test operational feasibility, helping u evaluate EMIF-Platform architecture scientific research perspective. Theme 6: Publication Strategy 5G EMIF-Platform consortium also focused prioritizing publication remainder project. Within remainder IMI program, plan promote external publication EMIFs technological, methodological, scientific activities. need ensure research community large becomes familiar EMIF developments, invite interested party . Progress Future Work 5H discussion 9th EMIF-Platform consortium revealed work limited time remains, also recognize EMIF ha made significant contribution field real world data health research. work past four year ha proven critical sustainable, integrated platform diverse data source collaborations, based harmonized approach federated network model. partner collaborator rightfully proud achievements. focus energy need done rest 2017. must create operational model sustain European medical research via real world data 2018 beyond. would like support future EMIF, please contact . content Copyright EMIF, right Reserved. Last update 08-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation EMIF NEWSLETTER (NOVEMBER 2017) November2017 Use button jump article issue. Subscribe Newsletter, please complete . NOVEMBER 2017 01 Improving Access Human Health Data: EMIFs Commitment Collaboration EMIF ha made great progress several area 2013 2017. (EMIF) wa launched (IMI) January 2013, high hope five-year project. wanted increase access human health data, improving life science research bringing better safer medicine patients. IMI-funded phase EMIF project drawing close June 2018, wed like take opportunity reflect journey. KEY POINTS Innovative Medicines Initiative (IMI) funded phase EMIF project come close end June 2018. past five years, EMIF ha facilitated collaboration make major breakthrough tool development, cohort development, biomarker discovery. EMIF team member wrapping existing project also working create sustainable environment collaboration continue flourish. CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIF-PLAT Janssen Pharma R&D Collaboration Key 1A goal wa monumental, knew could make progress collaborating. past five year (20132017), EMIF ha brought together academic centre excellence, subject matter experts, industry giants, patient organization. combined 57 partner across 14 European country 56 million worth resources, focusing three major projects. Collaboration grand scale ha made EMIFs achievement possible. Major Projects Achievements 1B progress toward EMIFs goal, developed framework () evaluating, enhancing, providing access human health data across Europe. help guide development EMIF-Platform, chose two pressing area therapeutic research: onset Alzheimers disease () metabolic complication obesity (). achievement past five year even greater initially hoped. hosted (i~HD) EMIF, Professor Dipak Kalra, President i~HD, introduced EMIF follows: wanted example best big data medicine, EMIF would it. three project area made major breakthrough tool development, cohort development, biomarker discovery. shared discovery around world, including 117 scientific publication published, 189 public presentation orated EMIF, 75 poster presented conference (2013 August 2017). Speaking collaboration conferences: pleased working Erasmus Medical Centre development (OHDSI) European Union (EU) Chapter. first annual scheduled , Erasmus Medical Centre Rotterdam, Netherlands. Collaborations organization OHDSI ensure EMIFs mission continue even IMI-funded phase EMIF project concluded. Looking Future 1C phase project wrapping up, doe mean stop striving increased access human health data. fact, find need growing time. countless potential application real world data drug development, discovery development launch post-launch. always need improving life science research bringing better safer medicine patients. Potential application real world data drug development. EMIF wrap existing projects, also working create sustainable environment collaboration continue flourish. 10th final December 45, 2017, Barcelona focus celebrating achievement ensuring sustainability. proud work EMIF ha accomplished date, cannot wait see lead future. Contact information continuing collaborate future. NOVEMBER 2017 02 Realizing Value Health Data: 2017 Joint Meeting Hosted i~HD EMIF Madrid September 21 22, 2017, i~HD EMIF hosted joint meeting Hospital Universitario 12 de Octubre, Madrid, Spain. September 21 22, 2017, (i~HD) (EMIF) hosted joint meeting Realizing Value Health Data Improving Care Research. Well 200 delegate attended meeting, took place Hospital Universitario 12 de Octubre, Madrid, Spain. KEY POINTS 200 delegate attended September joint meeting hosted European Institute Innovation Health Data (i~HD) European Medical Information Framework (EMIF) Madrid, Spain. meeting focused value reusing clinical data improving health care clinical research. Multiple presenter panellist highlighted important role trust reusing health data. CONTRIBUTORS JELLE PRAET, PhD Project Manager Janssen Pharmaceutica Reusing Clinical Data 2A first day meeting wa hosted i~HD. kick-off session, representative Spanish Estonian health ministry elaborated importance reusing clinical data improving health care clinical research. addition, emphasized need dialogue patients. explained essential tell patient result achieved allowing reuse data. Representatives Spanish Estonian health ministry elaborate importance reusing clinical data improving health care clinical research. Trust 2B remainder morning, goal challenge transition toward value-based outcomes-based health care discussed. Mary Baker, chairperson session, stated, stop talking cost health care start talking investment health long run. second half day examined empowerment patients. integral aspect patient empowerment development solution lead healthy data ecosystem. ecosystem must quality data also place high priority trust. mutual trust bona fide reuse data utmost importance advance field. patient representative put it: end, trust. EMIF Takes Stage 2C EMIF-AD Project Achievements second day meeting, EMIF project took stage. Professor Dipak Kalra, President i~HD, introduced EMIF follows: wanted example best big data medicine, EMIF would it. day started overview EMIFs achievement building using EMIF platform, also applying tool field Alzheimers obesity. past five years, EMIF ha developing common technology governance framework. addition, EMIF ha creating online platform identification, assessment, access, reuse health data across academia, industry, payers, governments. EMIF ha two disease focus evaluate framework:(EMIF-AD) and(EMIF-MET). Researchers working apply EMIFs tool technology identify novel biomarkers Alzheimers metabolic diseases. EMIF-AD EMIF-MET made significant achievements. EMIF-MET Project Achievements Greater Benefit Patients 2D Throughout day, presenter spoke many different aspect reuse health data, discussing audience. Among aspect discussed technical ones, harmonization electronic health record data (via collaboration , OHDSI). Presenters also spoke harmonization AD cohort data Switchbox common data model wa developed within EMIF specifically purpose. Additionally, presenter raised many non-technical aspect regard governance, expansion data source collaborations, sustainability legacy EMIF elements. Bart Vannieuwenhuyse (EMIF Coordinator; Senior Director, Janssen Pharmaceutica) speaks attendee second day joint meeting. day ended panel discussion. Panel member asked hoped would legacy EMIF. Michel van Speybroeck Janssen Data Sciences replied, ultimate objective work put result improved health outcome everyone. hope succeeded laying foundation data ecosystem health data reused good trust greater benefit patients. Nigel Hughes, EMIF-Platform Co-Coordinator Janssen Pharma R&D, added final thought Michels, saying, 80% bioinformatics humans, data itself. Professor Sir Simon Lovestone, EMIF Co-Coordinator professor translational neuroscience, Oxford, agreed: get patient partner involved trust other, couple endless ambition, really make difference patient lives. NOVEMBER 2017 03 Bridging Europe: First Annual European OHDSI Symposium Scheduled March 2018 First Annual European OHDSI Symposium take place Rotterdam March 2018. (EMIF) project main objective develop sustainable platform enables data discovery unprecedented use data source wide variety types, including Electronic Health Records (EHR) primary hospital care. challenging task data source ha underlying data model, make use common tool difficult extraction process le transparent. Differences clinical terminology system complicate study across European data sources. KEY POINTS European Medical Information Framework (EMIF) ha adopted Observational Medical Outcome Partnership Common Data Model (OMOP-CDM), developed Observational Health Data Sciences Informatics (OHDSI) Initiative, standardize European data source common structure language. EMIF working Erasmus Medical Centre develop European OHDSI Chapter. first annual March 2324, 2018, Erasmus Medical Centre Rotterdam, Netherlands. CONTRIBUTORS PETER RIJNBEEK Assistant Professor, Department Medical Informatics Erasmus University Medical Centre Data Standardization Rescue 3A EMIF overcome challenge? embracing (OHDSI, pronounced Odyssey) model translating data common structure language. might recognize conceptits known data standardization. EMIF mapping European data source common data model developed OHDSI. also extending OHDSI tool enable large-scale analytics key EMIFs core objectives. Origins OHDSI 3B , public-private partnership originally established United States. OMOP project developed initial version (OMOP-CDM), accommodate health data diverse source consistent standardized way. OHDSIs mission improve health, empowering community collaboratively generate evidence promotes better health decision better care. key objective stimulate transparent reproducible research OMOP-CDM prerequisite. Today, OHDSI international collaborative comprised academics, industry scientists, healthcare providers, regulator come together create apply open-source data analytic solution large network health databases. non-funded entity, supported generosity passion individual member well in-kind contribution many organizations. OHDSI powered spirit global collaboration. New Chapter OHDSI 3C EMIF pleased working Erasmus Medical Centre development European OHDSI Chapter. first annual scheduled March 2324, 2018, Erasmus Medical Centre Rotterdam, Netherlands. Erasmus Medical Centre Rotterdam host first annual European OHDSI Symposium (source: ). symposium called Bridging Europe. aim establish European community actively contributes global OHDSI mission. symposium, participant share result idea use OMOP-CDM, tool development, future research studies. meeting feature collaborator showcase involving poster session highlight OHDSIs research achievement interactive demonstration OHDSIs open-source software tools. Standardizing European health data enable distributed research study unprecedented scale, say Dr Peter Rijnbeek, Assistant Professor Department Medical Informatics Erasmus University Medical Centre. annual OHDSI symposium perfect instrument stimulate support transition. Join exciting journey! Register 3D active participant EMIFs work utilizing OMOP-CDM? new OHDSI interested learning exciting initiative? Whatever level experience, welcome. Registration limited 250 participants, please soon possible reserve spot. NOVEMBER 2017 04 Celebrating Achievements Ensuring Sustainability: 10th Final EMIF-Platform Consortium Meeting EMIF-Platform infrastructure Electronic Health Records (EHRs). past five year (EMIF) project, (EMIF-PLAT) worked closely many colleagues, including University Aveiro Portugal. Together, developed integrated platform facilitate access diverse medical research data source across Europe. sustainable framework support identification, assessment, use reuse health data medical research. Two track EMIF architecture support two data types: Electronic Health Records, include routine healthcare data general practice hospitals; cohort datasets, include data specific research communities. KEY POINTS European Medical Information Framework (EMIF) Platform community gather final consortium meeting December 45, 2017. meeting focus learning Use Cases might taken consideration final Platform. Another topic meeting sustainability, including publication strategy, business planning, legacy. EMIF need work inclusively progress sustainable element continue beyond Innovative Medicines Initiative (IMI)funded phase project. CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIF-PLAT Janssen Pharma R&D Looking Forward 4A Barcelona May 2017, many important milestone discussed, including technology platform, data harmonization, sustainability, research use cases, expedited research efficiency, publication strategy. EMIF-PLAT community gather final consortium meeting December 45, 2017. 10th final consortium meeting, member evaluate progress date well discus final activity end project Jun 2018. 10th meeting likely reflect one well-known achievements: going public January 2017. 400 user registered EHR community Catalogue. Since January 2017, continued work data harmonization electronic health record data custodian via . ha involved work evaluating data fidelity. EMIF Catalogue homepage. EMIFs collaboration OHDSI ha made much data harmonization work possible. pleased working Erasmus Medical Centre development OHDSI European Union (EU) Chapter. first annual scheduled March 2324, 2018, Erasmus Medical Centre Rotterdam, Netherlands. Onboarding New Cohorts 4B 10th meeting, also evaluate work additional (EMIF-AD) cohorts. Using Switchbox common data model, onboarded cohort EMIF-Platform. onboarding new cohorts, make sure populate participant variable selection tools. tool allow researcher identify subsamples individual subset variable fit need research questions. work support establishment EMIF-AD platform sustainable infrastructure, crucial AD research Europe. Expedited Research Efficiency 4C consortium meeting explore manage research efficiently. currently considering potential use commercial-like study evaluate whole EMIF-Platformfrom Catalogue private remote research environmentprior end EMIF project. order expedite research efficiency, also identified bottleneck research process need addressed, well technology supporting research via EMIF-Platform. Prioritizing Publications 4D Since meeting May, EMIF-PLAT community ha working publication project. look forward fact 10th consortium meeting include discussion member submission relevant journals. excerpt extensive . Working Inclusively 4E considerable work prior official end EMIF project five-year mark. need work inclusively progress sustainable element continue beyond IMI-funded phase. excited upcoming consortium meeting celebrate work achieved, shepherd project successful conclusion, solidify plan sustain EMIF-Platform future. content Copyright EMIF, right Reserved. Last update 08-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation EMIF NEWSLETTER (MAY 2018) May 2018 Use button jump article issue. Subscribe Newsletter, please complete . MAY 2018 01 Shining Yet Light: Impact European Medical Information Framework Project Theres old joke go something like this: policeman came across man hand knee street light late night. doing, sir?, said policeman. man replied, lost car key looking them, continued search. policeman replied, Ill give hand. Whereabouts think dropped them? response, man said, alley there, think. policeman rubbed jaw said, Well, searching then?. man retorted, Well, light is. KEY POINTS European Medical Information Framework (EMIF) wa formed liberate insight evidence real world data Europe. Collectively, brought together remarkably diverse research development effort within EMIF address key challenge modern healthcare. EMIF ha done much grow community, platforms, infrastructures, case enabling reuse data Europe. CONTRIBUTORS PROF SIR SIMON LOVESTONEProfessor Translational Neuroscience, Oxford University, Overall joint program lead EMIF BART VANNIEUWENHUYSESenior Director, Janssen Clinical Innovation Patient Data Research (JCI-PDR), Coordinator overall EMIF project Bringing Light Needed space need look answer pressing question medicine today alley, lamppost. (EMIF) wa formed bring light needed; wanted shed light potential key liberating insight evidence real world data Europe. transformation taking place, healthcare becoming truly data-driven sector, clinical care R&D. Compared many industry society, healthcare ha latecomer digital realm. However, last five six year since EMIF wa first imagined, healthcare truly moving digital realm, project ha contributed change. newsletterthe last IMI projectwe bringing together view around EMIF project achieved, wa challenge, lesson learned, could going near future. Achieve Collaboration EMIF ha complex project three components: socio-technical governance framework (), two disease projects, Alzheimers disease () metabolic consequence obesity (), working early biomarker development. Collectively, brought together remarkably diverse research development effort within EMIF address key challenge modern healthcare. Moreover, recognised achieve collaboration, working together clinical data generated potentially analysed latest open-source tools. final meeting consortium public event spoke remarkable achievement EMIF involved it, well challenge lesson learned. covered much within newsletter. doubt working scalewith increasingly large cohort collaboration data custodian internationally eventually globallyis going standard real world observational health research. especially case cohort linked complementary datasets, molecular imaging data used part EMIF. learnt much develop nurture federated data network, value indeed challenge linking observational data basic science two disease areas. Importantly, learning together. ha transformed knowledge led productive lasting scientific collaborations. Thank result EMIF contained newsletter, also would want take opportunity thank involved collaborating EMIF. project ha set stage new project impending, IMI2 European Health Data Evidence Network (EHDEN), hope start later year. Meanwhile, sustainable element EMIF accessible beyond IMI phase research community. EMIF already contributing infrastructure projectsproviding contributing harmonisation within example. Setting New Precedents EMIF ha outstanding success, evidenced one highest citation impact IMI project, scientific output three domain continue reverberate many years. Insights generated into, instance, variable progression Alzheimers disease, liver-related consequence obesity, utilisation common data model harmonising diverse European data, set new precedents. EMIF ha done much grow community, platforms, infrastructures, case enabling reuse data Europe. look forward legacy carried forward, least IMI programme initiative well EMIF continuation plans. done much make EMIF success proud work done. hope enjoy reading work EMIF newsletter many scientific paper come, shining yet light key medical societal challenge may found. MAY 2018 02 Achievements, Lessons Learned, Opportunities: Reflecting Past Five Years EMIF five-year (EMIF) project draw close, EMIF topic lead reflected achievements, lesson learned, future opportunities. topic lead would like share thought hope increasing sustainability EMIFs legacy. KEY POINTS European Medical Information Framework (EMIF) project ha made major contribution towards promoting reuse healthcare data developing tool purpose applying tool field Alzheimers disease metabolic complication obesity. EMIFs mission improve access re-use healthcare data ha accomplished large extent, sustainability crucial order leverage full potential EMIF. EMIF ha resulted new collaboration project lead hope continue future. CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIF-PLAT, Janssen Pharma R&D ULF SMITHProfessor, University Gothenburg, Public lead Metabolic topic JOHANNES STREFFERVP Head Early Clinical Neurology, UCB, EFPIA lead AD topic PIETER JELLE VISSERAssociate Professor, Maastricht University, VU University Medical Center, Public lead AD topic DAWN WATERWORTHDirector Genetics, Cardiovascular, Metabolic Dermatology, GSK, EFPIA lead Metabolic topic Achievements Made Possible EMIF Nigel Hughes, (EFPIA) Coordinator , say EMIF created community disparate diverse stakeholder common goal around real-world, observational research. stakeholder fostered scientific technical achievement project. One major achievement project common information framework, , link facilitate access diverse medical research data sources. past five years, EMIF ha created working platform mapped multiple database . representing process data standardization using OMOP Common Data Model. According Johannes Streffer, EFPIA lead , EMIF foster strengthens relationship among partner data providers, connects research center effectively. EMIF-AD ha also developed tool (with cohort patient selection tools), tranSMART, Switchbox. Pieter Jelle Visser, public lead EMIF-AD, note tool possible EMIF combination different type expertise. tool pooled datasets enabled EMIF-AD perform large meta-analyses fraction cost fraction time would taken otherwise. EMIF-AD Catalogue. EFPIA lead , Dawn Waterworth, say without EMIF, would able access electronic medical record (EMR) database Europe run parallel analysis four databases. also able bring together multi-disciplinary team appropriate skill knowledge take advantage data, would difficult otherwise. According Ulf Smith, public lead EMIF-Metabolic, scientist complementary expertise work carefully phenotyped cohort ha crucial validating importance novel biomarkers. Mission Accomplished EMIF ha achieved mission developing common technical governance solution facilitating access use healthcare data. EMIF helping liberate insight within Alzheimers disease, metabolic disease co-morbidities, within project series use cases, externally via Catalogue, say Nigel. EMIF-AD Catalogue ha 400 registered users, clearly indicating meet strong need. remain challenges, especially around governance provenance local data external engagement stakeholders. topic lead agree sustainability essential continuing EMIFs mission leverage full potential EMIF. Lessons Learned topic lead agree time spent building community within three area EMIF (Platform, AD, Metabolic) wa valuable. EMIF-AD, topic lead happy team achieved deliverable clearly transparently, created cohort infrastructures, re-used existing data. EMIF-Metabolic topic lead say project led great collaborations, pleased access complementary expertise large cohort disease outcome data. future similar projects, topic lead aspirations. One key building federated data network real world, observational research Europe gaining understanding data source local governance provenance requirements. Future project also focus stakeholders, communicating opportunity possible reward partner organization data providers. would allow better utilization access data infrastructure. long-term project like EMIF, topic lead would advise EFPIA partner hire people specifically work project, make sure time available it. Beyond EMIF topic lead agree EMIF project resulted new high-level collaboration hope continue beyond five-year span project. EMIF-Platform, wa collaboration around OMOP common data model. Within EMIF-AD, wa linkage between, example, (IMI EPAD), (DPUK), et al, well wider Alzheimers research community. EMIF-Metabolic, collaboration number EFPIA academic participant continue future. Johannes says, Collaborations within existing partnership strengthened strong driver research initiatives. New partnership built hopefully develop. Nigel suggests development already taking place: believe EMIF cemented relationship academia, industry/EFPIA partners, data source pre-competitive state. would suggest paved way forthcoming European Health Data Evidence Network (EHDEN) IMI2 project. exciting see legacy EMIF action form project EHDEN. MAY 2018 03 Bridging Europe: First Annual OHDSI Symposium Participants March 2018 OHDSI Symposium Rotterdam, Netherlands, wearing jacket OHDSI Europe logo. March 23 24, 2018, European (OHDSI) chapter hosted first annual OHDSI symposium theme Bridging Europe. Well 200 people attended meeting (140 attending OHDSI event first time), representing 24 different countries. Many attendee several speaker directly involved (EMIF). meeting took place Erasmus Medical Center, Rotterdam, Netherlands. Participants successfully contributed expanding already vibrant European Union (EU) OHDSI community. KEY POINTS 200 participant attended first annual European Observational Health Data Sciences Informatics (OHDSI) symposium, hosted Rotterdam, Netherlands, EU OHDSI chapter. first day symposium, presenter spoke adoption Observational Medical Outcomes Partnership (OMOP) common data model (CDM), need EU OHDSI initiative, importance OHDSI tools, more. second day symposium, two workshop gave participant hands-on experience OMOP CDM OHDSI tools. CONTRIBUTORS JELLE PRAET,PhDLife Science consultant CMAST bvba, subcontractor Janssen Pharmaceutica PETER RIJNBEEK, PhDAssistant Professor Erasmus University Medical Center Importance OMOP CDM George Hripcsak (Vivian Beaumont Allen Professor Chair, Biomedical Informatics, Columbia University Medical Center; Director, Medical Information Services, NewYork-Presbyterian Hospital) wa first speaker day. presented worldwide journey OHDSI adoption Observational Medical Outcomes Partnership (OMOP) (CDM). Currently, 400 million patient 1.26 billion patient record mapped OMOP CDM. Among user large institute like (FDA), (eMERGE), (NIH), (IMI). Peter Rijnbeek (Assistant Professor, Department Medical Informatics, Erasmus MC Rotterdam) elaborated need EU OHDSI initiative. many different database structure coding system Europe, healthcare system differ considerably across EU countries. Harmonization OMOP CDM critical generation real world evidence fast reproducible way. current one study one script approach scalable transparent; moreover, expensive, slow, prohibitive non-expert use. EU OHDSI initiative stimulate adoption OMOP CDM Europe, providing platform European collaboration improve CDM vocabulary European setting. Patrick Ryan (Sr. Director Head, Epidemiology Analytics, Janssen R&D; Adjunct Assistant Professor Biomedical Informatics, Columbia University) gave last talk first session. last talk first session wa given Patrick Ryan (Sr. Director Head, Epidemiology Analytics, Janssen R&D; Adjunct Assistant Professor Biomedical Informatics, Columbia University). want science reproducible others, even harder able repeat results, said Patrick. want science become reproducible, need ensure every step along research process identical. exactly OMOP CDM OHDSI tool important. product community working together define community standard tools, share evidence, define best practices. Adoption OMOP CDM coffee break, different case adoption OMOP CDM shown. Nigel Hughes (Scientific director, JCI Patient Data Research, Janssen, Belgium) presented upcoming IMI European Health Data Evidence Network (EHDEN) project, ha set goal mapping 100 million health record across EU OMOP CDM next five years. goal ambitious, Nigel Hughes expressed confidence could reach it. EHDEN blank canvas, build ha already developed project (like, example, EMIF). Martin Sedlmayr (Professor, Institute Medical Informatics Biometry, TU Dresden, Germany) presented Medical Informatics Research Care University Medicine (MIRACUM) consortium. Martin Sedlmayr (Professor, Institute Medical Informatics Biometry, TU Dresden, Germany) introduced (MIRACUM) consortium. Recently launched supported German government, MIRACUM consortium currently represents quarter German university hospitals. aim stimulate reuse data adopting OMOP CDM OHDSI tools. Ben Hughes (Senior Vice President Real-World & Analytics Solutions, IQVIA) discussed IQVIA, formerly Quintiles IMS, continuously investing OMOP CDM. IQVIA help many large-scale institution (such FDA ) answer simple complex question drug safety, adverse-event reporting, more. Following trial 12 database harmonized OMOP CDM, IQVIA convinced OMOPs huge potential help better research, IQVIA also remains realistic associated cost time requirements. Rae Woong Park (Professor, Ajou University School Medicine, South Korea) presented journey South Korea successfully adopted OMOP CDM. currently many participating hospital South Korea total 55 million patients. Despite effort Professor Park, promoting Korean OHDSI initiative, took 18 month first hospital expressed interest joining Korean OHDSI initiative. change came May 2016, due Korean National Health Insurance system started using OMOP CDM. story, learn need get EU payer regulator board supporting EU OHDSI initiative want successful. Epidemiological Presentations Daniel Prieto (Associate Professor NIHR Clinician Scientist, Oxford University, UK) introduced work group Oxford, showing audience epidemiological work using patient record help study risk benefit medical devices. Erica Voss (Associate Director, Epidemiology Analytics, Janssen R&D, US) gave overview type research done Janssen epidemiology analytics. explained real-world data used conduct clinical trial feasibility studies, design trial use real world data validate trial feasible need tweaking. mentioned adoption OMOP CDM ha required substantial investment time money, ha strong return. invest, get it. Sir Simon Lovestone (Professor Translational Neuroscience, Oxford University, UK) spoke (UK-CRIS) system, hold data 2.5 million mental health patients. data mental health patient written long text, pose tremendous challenge harmonizing data. Currently, UK-CRIS implementing consent re-contact model 74% patient agreed contacted again, tremendously speed clinical trials. OMOP CDM Tools Action lunch, wa time several demonstration tool related OMOP CDM 40 research posters. demonstration included patient-level prediction package R, research network platform, new features, tool, . latter wa presented Jos Lus Oliveira (Associate Professor, University Aveiro; Vice Director Institute Electronics Informatics Engineering Aveiro) showed audience complete EMIF Catalogue pipeline discovery, assessment, way re-use health data. Prof. Dr. Jos Lus Oliveira gave real-time demonstration EMIF Catalogue, online platform integrates enables discovery reuse heterogeneous biomedical databases. Regulatory Considerations panel discussion, Jim Slattery (Senior Statistician, European Medicines Agency) mentioned regulator use observational data guide decision making. Christian Reich (Vice President Real World insights, IQVIA) stated lack reproducible research base decision problem company, institution, government solve own, matter rich are. asked OHDSI community make sure compliant new EU General Data Protection Regulation (GDPR), Michel van Speybroeck (Director Data Sciences, Janssen, Belgium) replied exact interpretation GDPR debatable, new rule regulation might interpreted differently different levels. However, OHDSI approach use federated data network (versus centralized), much easier compliant new GDPR. Peter Rijnbeek (Assistant Professor, Department Medical Informatics, Erasmus MC Rotterdam) closed first day symposium hilarious show closure past OHDSI symposium US, including singing section greatly appreciated participants. Hands-on Experience OHDSI Tools second day conference hosted two workshops, allowing participant get hands-on experience OMOP CDM OHDSI tools. end day, participant better understanding detail OMOP CDM structure Standardized Vocabularies used harmonize data. tool ecosystem OHDSI community wa also shown, strong focus ATLAS tool, allows browsing vocabularies, defining cohorts, estimating risk effects, making patient-level predictions, more. Information information OMOP CDM OHDSI community, stay date next edition symposium, please visit . MAY 2018 04 Achievements Challenges Five Year IMI Project: Final EMIF General Assembly Meeting Public Symposium 110 people attended EMIF public symposium April 18 discus learn European health data ecosystem. April 16 17, 2018, (EMIF) project held final general assembly meeting Hotel Bloom, Brussels, Belgium (BE), project wa launched five year prior. addition, public symposium Liberating Evidence European Health Data wa hosted April 18. KEY POINTS European Medical Information Framework (EMIF) project held final general assembly meeting public symposium Brussels, Belgium April 16 18, 2018. meeting, participant reflected research area Alzheimers disease metabolic complication obesity, well sharing poster demonstrating tool created EMIF. Discussions legacy sustainability led insight may helpful future IMI projects. CONTRIBUTORS JELLE PRAET,PhDLife Science consultant CMAST bvba, subcontractor Janssen Pharmaceutica Journey Thus Far general assembly meeting commenced Bart Vannieuwenhuyse (Janssen, BE) Prof Sir Simon Lovestone (University Oxford, UK) reflecting successful journey thus far. EMIF wa first conceived 2011. Since then, EMIF ha lived ambition providing enabling access unprecedented volume healthcare data, well accelerating research field Alzheimers disease (AD) metabolic complication obesity. Nigel Hughes (Janssen, BE) Johan van der Lei (Erasmus MC, NL) reflected social technical evolution EMIF project lifetime. One major challenge EMIF ha fact fly plane building it, said Nigel. Part success EMIF stem three topic together one overarching project, also introduced challenges, defining common goal across three topic academic (EFPIA) partners. major legacy EMIF development EMIF platform associated tools, well introduction (CDM) Europe. AD Metabolic Successes Johannes Streffer (UCB, BE) Pieter-Jelle Visser (Maastricht University, NL) explained ha focused heavily re-use enrichment AD cohort data. turn delivered new insight pathophysiology AD helped identify potential new AD biomarkers. Exemplars focused effort AD cohort catalogue, enriched EMIF Biomarker discovery cohort, establishment two new cohort extreme phenotype AD. asked would differently redo project, Johannes Pieter-Jelle replied political legal dimension working real world data overlooked, instead tackled soon possible future projects. Ulf Smith (University Gothenburg, Sweden) Dawn Waterworth (GSK, US) stated project structure three different topic ha also critical success . wa shared interest EMIF-AD study link dementia insulin resistance, kind research wa possible due collaboration EMIF-Platform. Working together ha enabled u identify mannose new marker insulin resistance, answer critical question risk factor link progression non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), heart failure. Dawn Waterworth (GSK, US) presented journey geneticist working field real world data. Poster Prizes Tool Demonstrations first day ended poster session. addition 28 posters, also three real-time demonstration tool developed EMIF. Myriam Alexander (formerly GSK, UK) took home jury poster prize public poster prize wa awarded Stephen Carter (University Manchester, UK). Cohort Research second day general assembly meeting started session work undertaken relates using cohort-related data. Isabelle Bos (Maastricht University, NL) Sarah Westwood (University Oxford, UK) presented outcome cerebrospinal fluid (CSF) analysis proteomic analysis done context multimodal biomarker discovery study. Anouk den Braber (Vrije Universiteit Amsterdam, NL) presented result EMIF 90+ study PreclinAD study, two cohort focussing extreme phenotype AD. Claudia Langenberg (University Cambridge, UK) Luca Lotta (University Cambridge, UK) presented work using cohort data advance type 2 diabetes biomarkers mere association causal relationship. Naveed Sattar (University Glasgow, UK) introduced audience GlasVEGAs study, metabolic reaction Europeans South Asian men compared quickly gaining enforced weight. Michel van Speybroek (Janssen, BE) Rudi Verbeeck (Janssen, BE) explained performed harmonisation AD cohort datasets minimal dataset, hosted tranSMART platform. update wa also given AD cohort explorer associated AD Switchbox, developed make AD cohort data available wider research community. Upcoming White Paper break, wa interactive workshop, moderated Caroline Sage (CMAST bvba, BE). workshop asked participant reflect experienced EMIF lesson learned. outcome workshop combined result earlier survey conducted within EMIF published white paper. interactive workshop, people split eight different groups, asked reflect experienced EMIF field continue evolve year come. EHR Research lunch, wa session outlining use electronic health record (EHR) data. Naveed Sattar (University Glasgow, UK) presented result study investigated risk developing cardiovascular disease NAFLD patients. William Alazawi (Queen Mary University London, UK) showed u gap diagnosis disease assessment NAFLD literature EHR databases. Prof Sir Simon Lovestone (University Oxford, UK) explained group ha studying link dementia inflammation, specifically effect anti-inflammatory drug methotrexate. Rob Stewart (Kings College London, UK) showed u work using EHR data study dementia prevalence vascular risk factor dementia. Jos Lus Oliveira (University Aveiro, Portugal) guided u many different aspect (user profiles, database plugins Jerboa ACHILLES, community plugins TASKA ATLAS). Glen James (GSK, UK) told u experience using EMIF Catalogue answer actual research questions. Peter Rijnbeek (Erasmus MC, NL) presented Jerboa Reloaded tool wa developed within EMIF. Thereafter, switched gear explained work done OMOP CDM. addition, reported back successful (OHDSI) meeting Rotterdam, March, kick-off EU OHDSI chapter. Peter Rijnbeek (Erasmus MC, NL) holding microphone Q&A session project besides EMIF helping share European health data ecosystem. Legacy Scenario last session day, Nigel Hughes presented legacy scenario EMIF, followed panel discussion sustainability EMIF. Panelists included Bart Vannieuwenhuyse, Prof Sir Simon Lovestone, Pieter-Jelle Visser, Johannes Streffer, Johan van der Lei, Dawn Waterworth, Katrina Loomis (Pfizer, US). many (IMI) projects, moving towards sustainable entity ha proven difficult. general sentiment wa difficulty wa largely due many different stakeholder involved rather technological problem. Lastly, upcoming IMI project European Health Data & Evidence Network (EHDEN) wa often-recurring topic throughout discussion; EHDEN considered heir EMIF, thus big part EMIF legacy. Well-Attended Public Symposium Wednesday, April 18, 110 participant attended EMIF public symposium Liberating Evidence European Health Data. day started introduction EMIF Bart Vannieuwenhuyse Prof Sir Simon Lovestone. Thereafter, respective topic lead gave high-level overview tool technology developed EMIF (Nigel Hughes), new disease insight gained field AD (Johannes Streffer) metabolic complication obesity (Dawn Waterworth). Left: Bart Vannieuwenhuyse (Janssen, Belgium) gave audience warm welcome April 18 started public symposium giving high-level introduction EMIF project. Perfect Storm next session focused project currently impacting European health data ecosystem. Peter Rijnbeek discussed OMOP CDM revolutionize way healthcare data used Europe, allow generation evidence observational data fast reproducible manner. Peter remarked perfect storm, upcoming IMI project EHDEN help tremendously widespread adoption OMOP CDM throughout Europe. Next, Nemanja Vaci (University Oxford, UK) presented IMI (ROADMAP) project try develop efficient us real world evidence benefit AD patients. Adil Mardinoglu (Chalmers, Sweden) showed audience example large biological database help solve fundamental research question better understand disease pathologies. last speaker session, Gerald Luscan (Pfizer, FR), gave gave overview IMI (EPAD) project building platform accelerate clinical trial participant recruited EPAD Register. Perspectives Privacy lunch, Valentina Strammiello (European Patient Forum, BE) gave patient perspective re-use healthcare data. Interestingly, patient genuinely concerned data security privacy issues, want bona fide researcher able access data. Patients want involved control data. Thereafter, Nikolaus Forgo (University Vienna, Austria) gave audience crash course upcoming general data protection regulation (GDPR), effective May 25, 2018. Unfortunately, GDPR hoped-for revolution simplify European legislation data protection. penalty might higher breach GDPR, GDPR also offer relief opportunity allow use real world data research purposes. Next, wa panel discussion Past, Present, Future European Health Data Ecosystem. Panelists included Valentina Strammiello, Nikolaus Forgo, Isabelle Bos, Adil Mardinoglu, Thomas Allvin (EFPIA, BE), Daniel Prieto-Alhambra (Oxford University, UK). Many interesting topic discussed, as: consent better? Whats risk research real world data? keep sharing data GDPR effective? good enough job sharing outcome data research participants? Projecting Forward last session, projected forward, looking future health data ecosystem. Bo Saxberg (DDO Strategic Services, US) gave lecture evolving value real world data. augmenting currently available real world datasets, e.g., via inclusion longitudinal trajectories, tremendously increase value proposal dataset stakeholders. Pierre Meulien (IMI, BE) talked current challenge working healthcare data. mentioned IMI hope address challenge future focusing inclusion stakeholders, agile, scalable also sustainable, collaborating IMIs associated partner key initiatives. full meeting report slide public symposium, please visit . MAY 2018 05 Liberating Evidence European Real World Data: Odyssey EMIF Legacy Leaves overview EMIF Catalogue community contained therein. time writing, six week left prior official end (IMI) project known (EMIF, 20132018). EMIF ha one complex IMI project date, incorporating three project one: , technology governance framework; , Alzheimers disease, , metabolic consequence obesity. EMIF considerable aspiration vision wa first conceived circa 2011. European health data research domain wa different world then. time took project agreed upon IMI, initiated, implemented, saw remarkable change world ha moved digital realm, including healthcare. KEY POINTS EMIF-AD EMIF-MET contributed significantly understanding natural history Alzheimers disease metabolic consequence obesity, well identifying potential biomarkers. EMIF-PLAT ha developed modular architecture support identification, assessment, (re)use health data, conjunction overarching governance research process. EMIF platform continue beyond IMI project, led Erasmus MC, Rotterdam, support Synapse Research Management Partners Barcelona. European Health Data & Evidence Network (EHDEN), ambitious follow-up EMIF, anticipated take place 2018 2023. CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIF-PLAT, Janssen Pharmaceutica R&D One Cited Projects IMIs History EMIF-AD EMIF-MET contributed significantly understanding natural history respective disease areas, well identifying potential biomarkers. EMIF ha become one cited project IMIs history, publication forthcoming. Project lead EMIF-AD EMIF-MET concluded work, especially regard interaction large datasets, cohorts, population data, could accomplished following traditional route outside EMIF. Insights research process real world data come exploring diverse use cases, examining EMIFs ability respond research question within two domains, evaluating platform architecture. Work completed part EMIF ha also highlighted bottleneck research process well potential socio-technical responses. Meanwhile, EMIF-PLAT ha collaborated partner data custodian develop modular architecture support identification, assessment, (re)use health data, conjunction overarching governance research process. went live publicly accessible resource January 2016, approximately 25 researcher utilize Catalogue day. house number data communities, including population data source derived electronic health record (EMIF EHR), AD cohort (, , ), vaccine-related (), pediatric (). Additional data community formed. researcher granted access community Community Manager specific community interest, accessibility continue beyond IMI project. EMIF Research Process EMIF Platform wa developed considerable work multiple partner EMIF. University Aveiro led architecture development, Erasmus MC, Rotterdam, led data harmonization. EMIF platform support research process query hypothesis, catalogue-driven data source evaluation, protocol development, task management, data extraction analytical output private remote research environment. local governance provenance data custodian protected within federated network, processing tool distributed data source instead moving data central processing hub. visualization tools, documents, SOP process involved EMIF research process. part (OHDSI) global collaboration, EMIF ha also taken lead promoting utilizing (OMOP CDM), well assisting launch EU Chapter OHDSI. OMOP CDM ha played critical role within EMIF, making possible researcher data custodian collaborate harmonize data. Ambitious Follow-Up EMIF platform, based collaboration EHR data custodian cohort owner EMIF-AD, continue beyond IMI project. platform continue support open science, open source collaboration researcher data custodians, network network data sources. continued collaboration led Erasmus MC, Rotterdam, support Synapse Research Management Partners Barcelona. EMIF platform also provide socio-technical input future projects, including European Health Data & Evidence Network (EHDEN). EHDEN ambitious follow-up EMIF, currently progressing grant process IMI. anticipated start end 2018, five years. EHDEN could proposed without foundation provided EMIF. diagram showing flow information EHDEN. Learn look forward promoting EMIF legacy remainder project beyond. Anyone wishing consider conducting research via EMIF access find module EMIF platform well instructional material. information conducting research EMIF, please contact . content Copyright EMIF, right Reserved. Last update 08-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation EMIF WHITE PAPER (SEPTEMBER 2018) EMIF Public Symposium: Liberating Evidence European Health Data Wednesday, 19 September 2018 @ 17:54 Since Innovative Medicines Initiative (IMI) began 2008, ha funded many successful programme improve healthcare across European Union (EU), European Medical Information Framework (EMIF) ha exception. accomplishment made EMIFespecially area dementia, metabolic disorders, data harmonization produced proven model collaboration data management medical research. so, EMIF allowing research happen speed scale wa previously possible, say Bart Vannieuwenhuyse, Co-Coordinator overall EMIF project Senior Director Janssen Clinical Innovation Patient Data Research (JCI-PDR). content Copyright EMIF, right Reserved. Last update 04-01-2019. site us cookies. continuing browse site agreeing use them. Accept Toggle navigation CONTACT Fields asterisk (*) required First name Last name * Institution / Company Country Email * Enquiry * content Copyright EMIF, right Reserved. Last update 04-01-2019. site us cookies. continuing browse site agreeing use them. Accept